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Abstract 
Objective: Cervical cancer stands for the predominant cause of cancer death among 
Rwandan women. Chronic Human Papillomavirus (HPV) infection constitutes the main risk 
factor. We here assessed the prevalence and incidence of high-risk (HR)- and low-risk (LR)-
HPVs, low-grade and high-grade squamous intraepithelial lesions (LSIL and HSIL) and cancer 
and associated risk factors in 400 HIV- and HIV+ Rwandan women. Whether HPV testing 
could serve as a screening method for detecting HSIL was analyzed. We also assessed 
prevalence and curing rates of different sexually transmitted infections (STIs) and sexual 
behaviour. Advanced cervical cancer is often treated with radiotherapy. In an animal model 
for radiation cervicitis we wanted to assess how the normal uterine cervix responds to 
ionization radiation and whether hyperbaric oxygen therapy (HBOT) may reverse these 
responses. 
 Methods: Women were interviewed, screened for STIs (baseline and 9 months) and 
underwent cervical sampling for cytology and a test for 37 HPV strains. Cytological samples 
were taken again 9, 18 and 24 months later in 100 HIV- and 137 HIV+ women. We explored 
whether the single nucleotide polymorphism (SNP) rs1297860 in IL28B correlates with 
  
susceptibility to HPV infection and persistence as well as development of SILs. In the 
preclinical studies, rats underwent cervical irradiation and were either exposed to HBOT or 
no intervention. Immunological and oxidative responses induced by radiation were assessed 
and whether HBOT was able to reverse these responses. 
Results: HPV16 and HPV52 were the most common HPV strains. The sensitivity was 78% and 
the specificity 87% to detect HSIL with HPV screening. Chronic and incident HR-HPV infections 
occurred more frequently in HIV+ women than in HIV- women. HSIL or cancer was diagnosed 
in 38% of HIV+ women with persistent HR-HPV infections. The C/T and T/T genotypes of the 
IL28B SNP rs12979860 were more common in the group of women contracting HPV 
compared with women not contracting HPV. STIs were common in Rwandan women and the 
use of condoms was not affected by present STIs. TLR5, TRIF, NF-κB, oxidative stress (8-
OHdG) and antioxidant enzymes (SOD-1 and catalase) were up regulated, while cytokines 
were down-regulated 14 days after cervical irradiation. Changes in 8-OHdG and catalase were 
normalized after HBOT. 
 Conclusions: HPVs and STIs are common among Rwandan women. HPV screening may be of 
particular importance if provided for risk patients such as HIV+ women that develop more 
often persistent HPV infections and HSIL. Ionizing radiation induces oxidative stress and 
immune responses in the cervix that may be reversed by HBOT.     
Keywords: Human papillomavirus, cervical cancer, squamous intraepithelial lesion, screening, 
IL28B SNP rs12979860, Rwanda, radiotherapy, hyperbaric oxygen therapy 
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 SAMMANFATTNING PÅ SVENSKA 
Bakgrund: Cervixcancer utgör för den vanligaste cancerrelaterade dödsorsaken i Rwanda. 
Detta orsakas av en hög förekomst av humant papillomavirus (HPV) som är den viktigaste 
riskfaktorn för cancerformen. Vi undersökte prevalensen och incidens av hög-risk (HR)- och 
låg-risk (LR)-HPV, låggradiga och höggradiga skivepitellesioner (LSIL respektive HSIL) och 
cancer och kopplade riskfaktorer hos 400 HIV- och HIV+ rwandiska kvinnor. Vi undersökte 
också om HPV test kan utgöra en screeningmetod för att detektera HSIL. Vidare studerade vi 
prevalens av sexuellt överförda infektioner (STI) och sexuellt riskbeteende. Lokalt avancerad 
cervixcancer behandlas ofta med strålbehandling men är associerad med strålrelaterade 
biverkningar. I en djurmodell för strålcervicit undersökte vi hur strålning påverkar den 
normala cervixslemhinnan och om hyperbar oxygenterapi (HBOT) kan reversera förändringar 
inducerade av strålning. 
Metoder: Kvinnor intervjuades och screenades för STI vid baseline och vid 9 månader. Vid 
baseline, 9, 18 och 24 månader togs prov från cervix för cytologi och för screening av 37 HPV 
typer. Vi undersökte om single nucleotide polymorphism (SNP) rs1297860 i IL28B korrelerar 
med ökad risk för att infekteras av HPV och utveckla HPV persistens och SIL. Vi strålade cervix 
hos råttor och 14 dagar senare blev en grupp behandlad med HBOT och en grupp fick ingen 
HBOT. Immunologiska och oxidativa responser inducerade av strålbehandling undersöktes 
åren och om HBOT kunde reversera detta undersöktes 28 dagar efter strålning. 
Resultat: HPV16 och HPV52 var de vanligaste HPV typerna och HPV screening gav en 
sensitivitet på 78 % och en specificitet på 87 % för att detektera HSIL. Kronisk och incident 
HR-HPV infektion var vanligare hos HIV+ kvinnor än HIV- kvinnor. HSIL eller cancer vid 
cytologi förekom hos 38 % av HIV+ kvinnor som utvecklat persistent HR-HPV infektion. C/T 
och T/T genotyperna av IL28B SNP rs12979860 var vanligare hos kvinnor som smittats av HPV 
än kvinnor som inte smittats av HPV. STI var vanliga bland rwandiska kvinnor. De flesta HIV+ 
kvinnor uppgav användning av kondom vid samlag men HIV- kvinnor använde kondom i låg 
grad trots vetskap om STI. TLR5, TRIF, NF-κB, oxidativ stress (8-OHdG) och antioxidativa 
enzymer (SOD-1 och catalase) uppreglerades medan cytokiner nedreglerades i cervix 14 
dagar efter strålning. Förändringar i 8-OHdG och catalase normaliserades efter HBOT. 
 Konklusion: HPV och STI är vanliga bland kvinnor i Rwanda. HPV screening kan vara av stort 
värde för riskpatienter såsom kvinnor med HIV som oftare utvecklar persistenta HPV 
infektioner och HSIL. Strålning inducerar oxidativ stress och immunologisk respons i cervix 
som kan reverseras med HBOT.     
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1 GENERAL INTRODUCTION  
1.1 Introduction 
Rwanda is a landlocked small country in Central/Eastern Africa with 26.000 km
2
 of area and a 
population of around 12 million. The life expectancy of men is 66 years and of women 70 
years [1]. Rwanda, one of the poorest countries in the world is the country with the highest 
enrolment in health insurance in Sub-Saharan Africa [2]. It was also the first country in Africa 
to implement the cervical cancer vaccine with high coverage [3]. However like many other 
developing countries, Rwanda is in a phase of epidemiological transition. While 
communicable diseases remain the major causes of morbidity and mortality in the, the 
increasing incidence of non-communicable diseases i.e cancer and hypertension, results in a 
double burden of diseases [4]. 
This chapter discusses the background literature reviewed for this study. It describes the 
general characteristics of human papillomavirus (HPV) and its interaction with the immune 
system of the uterine cervix. The mechanisms involved in the development of HPV-induced 
cervical cancer, the current state on cervical cancer prevention strategies and the need to 
develop newer technologies better adapted to low-income countries are reviewed. Finally, 
the aims of the project showing the rational for this study and its contribution to the research 
are presented.  
1.2 Epidemiology of HPV infections and cervical cancer 
It is well known that chronic HPV infection is a risk factor to almost all cervical cancer cases 
[5]. Worldwide, 4.5% of all new cancer cases are associated with HPV infection [6]. Among 
these cases, cervical cancer accounts for 83% and women in less developed countries are the 
most affected [7]. According to the recent reports, worldwide cervical cancer ranks fourth for 
both incidence and mortality [8]. Each year more than half million women aged 15-44 years 
are diagnosed with the disease and more than a quarter of a million of die worldwide [5]. 
HPV16 and HPV18 infections are responsible for 70% of all cervical cancer cases worldwide 
[5, 9]. 
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1.2.1 Cervical cancer in sub-Saharan Africa 
Studies show that countries in sub-Saharan Africa (SSA) experience 85% of the total cervical 
cancer burden in the world [10]. In SSA, cervical cancer is the second most frequent cause of 
female cancer and the leading cause of female cancer deaths in women aged 15–44 years 
[11]. In 2017, there were 93,225 new cases of cervical cancer and 57,381 deaths were 
reported worldwide [12]. The annual age-standardized incidence and mortality rates are 
highest in East Africa (Malawi, Zimbabwe, and Uganda). These countries also have the highest 
HPV prevalence in the general population, i.e., (20.5% in the general population compared 
with globally 4.1% [11]. The age-standardized mortality rate for cervical cancer in East Africa 
was 28 cases per 100 000 women compared with only 3 cases per 100 000 women in North 
Africa [11] It is expected that due to aging population and growth of the population in SSA, 
but also to the lack of access to appropriate prevention services and concomitant human 
immunodeficiency virus (HIV/acquired immunodeficiency syndrome (AIDS) epidemic, cervical 
cancer incidence and mortality rates in SSA will rise over the next 20 years [9, 13-15].  
1.2.2 Type specific HPVs prevalence differs between Western 
countries and SSA 
In contrast to Western countries, in SSA, HPV16 and HPV18 contribute to only 60-65% of all 
cervical cancer cases [13]. HPV35, 45, 52, 56 and HPV58 are significantly more common in 
SSA than in Western countries [9, 13]. This contribution of HPV16 and HPV18 to the 
prevalence of cervical infection did not changed in 60 years [16]. Similarly to the Western 
countries however, the combined relative contribution of HPV16, 18, 31, 33, 35, 45, 52, and 
HPV58 to the total burden of cervical cancer was estimated at 91% [17] and the non-
oncogenic strains HPV6 and HPV11 are accountable for about 90% of genital warts. Few 
studies have been conducted on the prevalence of HPV in Rwanda. In HIV positive Rwandan 
women with normal cytology, HPV16, HPV35, HPV52 and HPV58 were found to be the most 
prevalent strains, while HPV16, HPV33 and HPV35 and HPV58 were found to be most 
prevalent among women with high-grade squamous intraepithelial lesion (HSIL or cancer 
[18]. In 2016, when we were conducting our HPV prevalence study (paper I), a large-scaled 
study in Rwanda showed that the most prevalent types among women with normal cytology 
were HPV 16, HPV52 and HPV35, whereas HPV16, HPV58 and HPV18 were the most 
prevalent among women with HSIL or cancer [19].  
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1.2.3 Cervical cancer in Rwanda 
Cervical cancer is the most common cancer-related deaths cause in Rwandan women. It is 
responsible for more than 1000 new cases diagnosed each year and it is classified as the 
leading cause of deaths among women of 15-44 years old [20]. However, the real number of 
cervical cancer cases may be much more in Rwanda due to poor access to health care in the 
country. Among HIV positive women in Rwanda, 46% are positive for carcinogenic HPV 
subtypes [18]. Studies in Rwanda show that 9% of HIV+/HPV+ women are diagnosed with 
cervical intraepithelial neoplasia (CIN) grade 3 [18, 21, 22].  
1.3 Human papillomavirus  
1.3.1  General characteristics  
HPV is a small, non-enveloped, double-stranded deoxynucleic acid (dsDNA) virus that belongs 
to the Papillomaviridae family [23]. There are five major known HPV genera: (1) α-
papillomavirus, (2) β-papillomavirus, (3) ϒ-papillomavirus, (4) mu-papillomavirus and (5) nu-
papillomavirus [23]. The oncogenic mucosal HPV types in the α-papillomavirus genus are a 
major cause of cervical cancer [24]. The viral genome can be divided into the early (E) and 
late (L) regions, containing open reading frames (ORFs) coding for viral proteins (Fig.1). 
Figure 1. HPV genome. Alpha-HPVs have a circular dsDNA genome of approximately 8000 base pairs [25] 
The E region encodes proteins (E1, E2, E4, E5, E6 and E7) involved in control of transcription, 
viral DNA and cell replication. The L region contains the genes that encode the viral capsid 
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proteins (L1 and L2). The classification of HPV is based on the nucleotide sequences of ORF. 
HPV infects epithelial cells and its replication cycle is closely linked to epithelial cell 
differentiation [26, 27]. In dividing basal epithelial cells, dsDNA episomal genome of the HPV 
enters the nuclei [28]. Upon basal cell division, an infected daughter cell begins the process of 
keratinocyte differentiation that activates a strongly organized pattern of viral gene 
expression to achieve a productive infection [29]. HPV proteins disturb different cellular 
processes in the epithelial cell. Two of the most important features are that E7 binds to and 
degrades the tumor suppressor Rb, while E6 binds to and inactivates the tumor suppressor 
p53 [30]. This leads to disruption and prolongs the normal cell cycle of the host cell, 
suppresses apoptosis and disposes the cell to neoplastic transformation [31]. 
1.3.2 Classification of HPVs  
HPV strains can be divided into mucosotropic types, which are mainly found on the mucous 
epithelium of the oropharynx and anogenital tract, and cutaneous types, which 
predominantly infect the skin [32]. Both types can be grouped in high risk (HR)-HPVs or 
oncogenic HPVs and low risk (LR)-HPVs or non-oncogenic HPVs [33]. In 2003, in a pooled data 
of 11 case-control studies from eleven countries by using GP5+/6+ primers, using GP5+/6+ 
primers, assessed HPV DNA assessed in 1918 women with cervical cancer and 1928 control 
women. HPV DNA was detected in 96.6% of cancer patients and in 15.6% of controls [33]. The 
authors classified 15 HPV strains as HR-HPVs (16,18,31,33, 35, 39, 45, 51, 52, 56, 58,59,68, 73 
and 82), 3 HPV types as probable HR-HPVs (26, 53, 66) and 12 HPV as LR-HPVs (6, 11, 40, 42, 
43, 44, 54, 61, 70, 72, 81 and CP108) [33].  
In 2008, three categories were suggested for the 51 established genital HPV types. Those 
categories are: (1) mild or possibly non-carcinogenic HPV category, including all the genital 
HPVs from G1 to G5 (G1: HPV61 and 61, 62,72, 81, 83, 84, 86, 87, 89, 102; G2: HPV71, 90 and 
106; G3: HPV7, 40,43,79 and 91; G4: HPV6, 11, 13, 44 and 74; G5: HPV32 and 42), (2) 
moderate or possibly carcinogenic HPV category, from G6 to G9 (G6: HPV18, 39, 45, 59, 68, 
70, 85 and 97; G7: HPV30, 53, 56, 66; G8: HPV 26, 51, 69 and 82; G9: HPV 34, 73) and  (3) 
severe or carcinogenic HPV category and from group G10  (G10: HPV16, 31, 33, 35, 52, 58 and 
67) [34]. In 2009, the International Agency for Research on Cancer (IARC) classified 18 HPV 
mucocutanous belonging to the α-genus, as HR-HPVs (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 
56, 58, 59) or probably HR-HPVs (HPV26, 53, 66, 68, 73, 82), while other 12 HPV types were 
classified as LR-HPVs (HPV6, 11, 40, 42, 43, 44, 54, 55, 61, 72, 81, 89). Twenty-five HPVs were 
classified as of undetermined risk (HPV2, 3, 7, 10, 27, 28, 29, 30, 32, 34, 55, 57, 62, 67, 69, 71, 
74, 77, 83, 84, 85, 86, 87, 90 and 91) [35].  
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1.3.3 Natural history of HPV infection 
Several studies have described the natural history of HPV infection and its association with 
the development of cervical cancer [36-43]. Here we will use a schematic model of the 
natural history of HPV infection and cervical cancer as presented by Patti E. Grant and Rachel 
L. Winer (2017) (Fig.2). We will also present some unresolved issues, which may impede the 
development of new tools for improving the management and prevention of HPV and early 
detection and treatment of HPV-associated cancer [44]. 
The natural history of cervical HPV cancer starts by HR-HPV infection via sexual exposure in a 
newly sexually active adolescent or a young adult women who are at the highest risk of HPV 
acquisition [45] . Studies show a peak for HPV infection prevalence around 20-25 years of age 
[46, 47]. This specific age is characterized with high sexual activity [45]. Other observations 
also support that the number of sexual partners and a young age at sexual debut strongly 
correlate with HPV infection [48]. The contribution of other viral related factors such as viral 
load and coinfection with other HR-HPV are still under discussion [49]. 
Figure 2.  Schematic model of the population-level natural history of human papillomavirus infection and 
cervical cancer: Purple boxes indicate well-accepted natural history model parameters; blue boxes 
represent uncertainties [50]. 
The majority (≈90%) of newly acquired HPV infections become cleared within 1-2 years [51-
54]. This is what we normally call “viral clearance”. During the productive HPV infection, low-
grade squamous intraepithelial lesion (LSIL) /CIN1 may be clinically detected but usually they 
are transients and cleared within 1-2 years [46, 55, 56]. Latent infections by HPV are also 
common [57]. Serum antibodies are generated in around 60% of the time following the HPV 
infection [58]. The minority of HPV infections is persistent and detectable over 12 months 
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and this long persistence increases the risk of carcinogenesis [46, 55, 56]. The virus clearance 
after long persistent infections are uncommon [50]. However several questions persist 
around the standard time for the infection to be qualified as persistent [49]. It is also difficult 
to distinguish a cleared infection to a latent, non-detectable infection [59]. Another issues 
resides in the definition of a new infection following a so-called clearance [50]. Some 
detected HPV infections could be the result of reactivation of a latent infection and not the 
result of contracting a new infection by sexual activity [60]. Women may also develop a 
reinfection not related to sexual exposure but due to an autoinfection from e.g. the anal area 
[61]. Most studies of the natural history of cervical HPV cancer failed to identify factors 
associated with clearance of HPV and regression of precancerous lesions [47].  
1.3.4 Clinical characteristics of HPV infection 
HPV infections are among the most common sexually transmitted infections (STIs). The 
majority of women acquire cervical HPV infection soon after the onset of sexual activity [62]. 
However, notwithstanding the fact that around 80% of sexually active women will face HPV 
at some point in their lives, the majority will experience natural elimination of HPV infection 
because of an intact immune system. HPV16 infection is eradicated within a two year-period 
in the majority of women [12, 63]. Persistent infection with a HR-HPV puts women at high 
risk of developing precursors of cervical cancer or carcinoma itself. Clinically, HPV infections 
manifest in one of three possible results, depending largely on which HPV type is involved. 
(i) The first results in latent or inactive infection, in which only few people know that they are 
infected, since visible symptoms are rarely produced and the infected area remains 
cytologically normal [64].  This infection is only detected by HPV DNA detection methods.  In 
the general population this is present in 2-44% of women and it can also be detected among 
women who are not yet sexually active [65]. 
(ii) The second results in subclinical infection with minimal clinical manifestations [66] which 
usually are diagnosed by colposcopy or cytology or histology [67]. These lesions represent 
60% of all external anogenital HPV infections and 95% of all cervical HPV infection [68]  and 
CIN is the most common manifestation of HPV in the cervix [69]. 
(iii) The third results is an active infection (clinical form) [70]. It is associated with HR-HPV 
types in which the virus causes changes in infected cells, which may result in penile, urethral, 
bladder, vaginal, vulvar, or cervical intraepithelial neoplasia[70]. HR-HPV types include types 
associated with HSIL/CIN3 and cervical cancer [71].  
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1.3.5 Determinants of HPV-related cervical cancer  
Chronic HPV infection does not constitute the only contributing factor to development of 
cervical cancer. These other variables are considered as determinants of HPV infection 
acquisition and persistence [72-77]. The importance of these HPV cofactors is justified in 
planning for cervical cancer preventive strategies, which will be discussed in the last part of 
this chapter. The following part summarizes what is already known and what is still to be 
clarified about relevant determinants of cervical cancer categorized under two categories: 
host and viral factors (Fig. 3). 
Figure 3. Several genetics and environment factors involved in susceptibility to cervical cancer [78]  
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Viral factors 
a) HPV infection and HPV types 
As mentioned, the most common HPV types causing cervical cancer are HPV16 and HPV18 
[16, 79]. CIN2/3 lesions associated with HPV16 are less likely to resolve spontaneously than 
those caused by other HPV strains [80, 81]. However, there is geographical variability in the 
distribution of other oncogenic HPV types [82].The reason for the variability is not yet 
identified but it has been speculation on the ethnogeographical differences contribution [83, 
84].  
b) Multiple HPV type infections 
Infection by multiple HPV types has been suspected to constitute a risk factor for cervical 
lesions to progress to cancer. Helen Trottier et al., (2006) found that infection with multiple 
types HPV seemed to act synergistically in carcinogenesis [85]. Wentzenzen N. et al., (2009) 
and Salzar KL et al., (2015) did not found any interaction/synergism in multiple HPV infections 
[86]. According to Cuschieri K.S and collaborators (2010), multiple HR-HPVs are not more 
common in HSIL than in LSIL [87]. Their finding was supported by the IARC, in concluding that 
women infected by multiple HPV types are not at higher risk of cervical cancer than those 
infected with a single HPV type [88]. 
c) HPV viral load 
Studies show that the development of cervical cancer precursors is associated with an 
elevated HR-HPV viral load [89-92]. Surprisingly, a study conducted on 2080 women followed 
for 10 years concluded that high HR-HPV viral load was not associated with the risk for 
development of CIN3+ [93]. Furthermore, Cheung Jo L.K.et al., 2009 in their study did not find 
any correlation between HPV18 load and an increase in cervical lesions severity [94].  
Host factors 
a) Sexual behaviour 
Most of HPV infections are acquired through sexual contact and acquisition is strongly 
associated with the number of sexual partners [95, 96]. Sexual behaviour in women and their 
sexual partners such as having multiple sexual partners [97] and vaginal intercourse at early 
age are known to put women at a higher risk of contracting HPV infection [98]. Several 
studies have found that young age at sexual debut as an important risk factor for HPV 
infection and for cervical cancer development [99-101]. For example, a large meta-analysis 
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study combined data from 10,773 women with invasive cervical carcinoma, 4,688 with 
CIN3/carcinoma in situ (CIS) and 29,164 women without cervical carcinoma (21 studies), to 
assess association between lifetime sexual partners or age at first intercourse and cervical 
carcinoma. As results, the analysis demonstrated the risk of developing either invasive 
cervical carcinoma or CIN3 to increase with the increase in number of lifetime sexual partners 
and the early age at first intercourse [102]. 
b) Parity 
High parity has been shown to be associated with an increased risk of cervical cancer [84, 98, 
103]. From a population-based study conducted among HPV infected and non-infected 
women, Hildesheim A et al., (2001) found multiparty (≥ 3 pregnancies) and smoking as risk 
factors for HSIL and cancer [104].  
c) Poverty 
Studies show that poverty is associated with a low age for beginning sexual activity [82]. 
Poverty is the strongest determinant of the incidence and of mortality of cervical cancer 
[105]. Globally, it has been shown that human development index (HDI) and poverty rate 
explain about 52% of the variability in cervical cancer [106-108]. In addition, factors such as 
lack of education, an employment, low socioeconomic level, rural residence and insufficient 
access to the health care were found to be associated with cervical cancer mortality [109]. In 
fact all those factors are related to the poverty [110]. 
d) Marital status 
Widows and separated women in Africa are at a higher risk for contracting HPV infection than 
married women due to risky sexual behaviour such as an increased number of sexual 
partners [111-115]. Unmarried women are less likely to seek medical attention for their 
health problem due to financial issues or due to the lack of family and social support [98, 
116].  
e) HIV infection  
Concomitant HIV infection has been shown to be an important risk factor for HPV infection 
[14, 15, 117, 118]. HIV infected women develop more often persistent HPV infection. Clifford 
GM et al., (2016) confirmed those results among HIV positive African women [119]. 
Furthermore, cervical cancer is considered to be an AIDS-defining illness [120, 121]. In a study 
from South Africa, it was demonstrated that women infected with HIV-1 presented with late 
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stage of cervical cancer at ages 15 years younger than HIV-negative women [122]. Studies 
suggest that there are synergistic interactions between HIV and HPV infections [14].   
f) HPV coinfection with STIs or other reproductive tract infections (RTIs) other than HIV 
STIs other than HIV constitute also a risk factor for incident and persistent HPV infections 
[123-125]. The change in vaginal microbiota has been shown to play a role in the acquisition 
and persistence of HPV and in the subsequent development and progression of CIN [126, 
127]. In addition, it is suggested that persistent infections caused by STIs increase the access 
of HPV into the deeper cervical tissue and cause cervical cell abnormalities [128, 129]. HPV-
infected women who have concurrent infections with chlamydia [130, 131], gonorrhea, 
cytomegalovirus [132] or Herpes Simplex Virus type-2 (HSV-2) [131, 133, 134] are at a greater 
risk for HPV persistence and development of cervical cancer. 
g) Smoking 
Smoking has been demonstrated to constitute a risk factor for cervical cancer in several 
studies [84, 135-137]. Smoking was the most significant environmental risk factor for cervical 
cancer in Sweden [138].  A pooled analysis of IARC multi-centric case-control studies 
confirmed smoking to increase the risk of cervical cancer among HPV positive women [139]. 
The presence of nitrosamine, a carcinogenic component in tobacco smoking [140], in human 
cervical mucus further strengthened the association between cervical cancer and tobacco 
smoking [141].  
d) Reproductive factors 
Long-term use of oral contraceptive for more than five years has been suggested to 
negatively affect the immune modulation effect of the body, which can lead to neoplastic 
changes in the cervical epithelium [84, 135, 142]. Contrary to this observation, a recent study 
on a cohort of 16-17 year-old women found the use of oral contraceptives to protect against 
cervical abnormalities [143]. The use of intrauterine device (IUD) may also constitute a 
protective cofactor against cervical carcinogenesis [79]. One theory put forward was that IUD 
protects against cervical carcinogenesis by triggering the cellular immunity [79].  
e) Host genetic factors 
Genetic factors in the host play an important role in the susceptibility to contract HPV 
infection and to develop cervical cancer. These factors may also regulate the rate of disease 
progression [144]. Variations in different immune response genes lead to subtle changes in 
the antiviral and anti-tumour immune responses, which eventually lead to differences in the 
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risk of developing cervical cancer [145]. Single nucleotide polymorphisms (SNPs) in immune-
regulatory genes may be associated with the risk of developing cervical cancer. SNP in the 
promoter of tumor necrosis factor-α (TNF-α) was associated with the risk to develop cervical 
cancer in a cohort of Argentinian women [146]. SNPs at rs361525, rs1800629, and rs1799964 
of the TNF-α promoter were also associated with an increased risk of cervical cancer in 
Chinese women [147]. SNPs in IL4, IL6, IL10 and transforming growth factor β (TGFβ1) have 
also been shown to be associated with the development of cervical cancer [148]. The toll-like 
receptor (TLR) 9 2848 G/A polymorphism was associated with the risk to develop cervical 
cancer in Chinese women [149]. Although the African population is characterized by a high 
heterogeneity, only few studies have been conducted in Africa on whether the immune 
system contributes to the susceptibility to contract HPV and develop cervical cancer. SNP in 
the chemokine receptor 2 (CCR2) showed that South African women with CCR2-64I variant 
had a higher risk to develop cervical cancer [150]. In Nigeria, SNPs at rs2305809 in ribosomal 
protein (RP) S19 and rs2342700 in thymidylase synthetase enzymes (TYMS) under allelic 
model were highly associated with prevalent HR-HPV [151]. In Rwanda there is a scarcity in 
the literature on cervical cancer and few available studies are limited on small groups of 
women. Thus, the generalizability of these results is not possible.  
1.4 HPV infection immunology 
1.4.1 Immune system defense against HPV induced cervical 
lesions 
The immune system protects the body from possibly harmful substances by recognizing and 
responding to antigens. Antigens are usually proteins on the surface of cells, viruses, fungi, or 
bacteria. Non-living substances such as toxins, chemicals, drugs, and foreign particles can also 
be antigens. The immune system recognizes and destroys or tries to destroy antigens that it 
recognizes as harmful. 
Human cervix description and immune system 
The cervix is the lower end of the uterus and both are parts of female genital tract (FGT; Fig. 
4).  In the adult, the ectocervical and endocervical region comprise 1/3 of the length of the 
uterus. The ectocervix is lined by a stratified squamous mucosa containing abundant 
glycogen. The underlying fibrovascular connective tissue of the lamina propria merges with 
smooth muscle bundles [152, 153]. At the cervical os, the squamous epithelium changes to a 
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tall columnar mucinous epithelium. This squamocolumnar junction is called the 
transformation zone (TZ).  
Figure 4. Human female cervix histology [154] 
Under the columnar mucosa in the lamina propria, there are prominent branching tubular 
glands also lined by a columnar mucosa producing mucin [7]. These are endocervical glands 
that extend into the lower uterine segment along the endocervical canal. The nature of the 
epithelial lining of the cervix varies according to location, with both columnar and squamous 
epithelia present at different locations within the cervix [65]. Most of the ectocervix consists 
of stratified squamous epithelium similar to that found in the vagina. The parts of the cervix 
closer to the uterus are covered by epithelia consisting of simple columnar epithelium, or 
rectangular column-like cells, which secrete mucus [65]. This glandular epithelium covers a 
varying portion of the ectocervix, as well as lining the endocervical canal [152]. The mucosal 
tissue of the cervix is a key factor for its immunity [155]. 
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Concepts of the innate and acquired immunity  
a) Innate immunity 
1. Cells of the innate immunity 
The innate immunity comprises the anatomic (skin and mucous membranes) and 
physiological barriers (temperature, pH, lysozymes and circulating factors such as interferon 
(IFN) and complements). It also comprises the inflammatory (cellular and chemical mediator 
of the inflammatory response) and phagocytic barriers (granulocytes, peripheral monocytes, 
tissue macrophages and dendritic cells). Macrophages and dendritic cells present antigens to 
be recognized by lymphocytes and therefore called antigenic-presenting cells (APCs) [156, 
157]. They also present foreign materials to the cells of the immune system and regulate the 
immune response [158, 159]. In addition, the innate immune system comprises natural killer 
(NK) cells, mast cells and the complement system [160]. 
2. Pattern recognition receptors and toll-like receptors 
Pattern recognition receptors (PRRs) are a family of receptors that recognize highly 
conserved antigenic structure, termed pathogen associated molecular patterns (PAMPs) 
[157, 161]. PAMPs are shared by large groups of pathogens. PRRs are secreted or expressed 
at the surface of the cells [162-164]. PRRs also recognize molecules that are released from 
damaged or necrotic host cells. Those molecules are called damaged-associated molecular 
patterns (DAMPs) [165]. TLRs constitute an important family of the PRR, mainly expressed on 
phagocytes and T-regulatory cells. Ten members of the TLR family have been identified in 
humans (TLR1, 2, 3, 4, 5, 6, 7, 8, 9,10) and each recognizes a small range of conserved 
pathogens molecules [166, 167]. The binding of PAMPs to TLRs induces the production of 
proinflammatory cytokines and the up-regulation of surface co-stimulatory molecules [168]. 
Recent studies have identified intermolecular signaling pathways specific for individual TLRs 
that lead to the release of cytokines specific for particular PAMPs [169]. The ability of 
individual TLRs to discriminate among different PAMPs is an important determinant of the 
unique gene expression profile activated in the host by different invading pathogens or 
environment danger signaling [170]. Thus, TLRs confers a certain degree of specificity for the 
innate immune response. Moreover, TLR-mediated recognition represents a cross-talk 
between the innate and the acquired immune system [171].Our focus on the innate immune 
system has been specifically on TLRs and their downstream molecules (Fig 5). 
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Figure 5. Simplified diagram of TLR signaling pathways [172] 
 Cytokines  
Cytokines are small-secreted proteins released by cells and have a specific effect on the 
interactions and communications between cells [173]. Many cell populations produce 
cytokines, but the predominant producers are CD4 helper T-cells and 
monocytes/macrophages. [174]. Cytokines produced by lymphocytes are called lymphokines 
while those produced by monocytes are called monokines. Other groups of cytokines include 
IFNs and chemokines [174]. Chemokines are cytokines with chemotactic properties that 
attract leucocytes to the infection site [175]. The general term interleukins (ILs) is used to 
define cytokines produced by leucocytes and acting on other leucocytes. They have been 
numbered in the order in which they were identified, thus the first interleukin identified was 
named IL-1. 
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b) Specific acquired immunity 
1. Lymphocytes 
Lymphocytes are the predominant cells involved in acquired immunity, which includes 
humoral and cell-mediated responses. Soluble antibodies presented in the serum mediate 
humoral response, while cell-mediated responses result from the interaction between 
different types of cells in the immune system [176]. This distinction correlates, respectively, 
with the existence of two types of lymphocytes: B-cells and T-cells [177]. Most of the T-cells 
belong to one of the two-sub populations distinguished by the presence on their surface of 
one of two glycoproteins, designated CD4 and CD8. The majority of CD4 T-lymphocytes are 
helper T-lymphocytes (Th) whereas the majority of CD8 T-lymphocytes are cytotoxic T-
lymphocytes (CTL) [178]. 
2. T-helper lymphocytes 
There are at least two subsets of helper T-cells (Th1 and Th2). While the Th1 subset produces 
large amount of cytokines that promote cell-mediated immune responses, the Th2 subset 
produces an environment favoring humoral immunity by providing B-cell help for antibody 
production [179]. The Th1 response is characterized by production of IFN-α, IFN-β and IFN-γ 
and IL-2. The characteristic of the Th2 response includes production of IL-4, IL-5, IL-9, IL-10 
and IL-13 [179]. The immune regulation involves homeostasis between Th1 and Th2 activity 
directing different immune response pathways [180].  
The immune system of the cervix 
Different regions of the cervix display different concentrations of immune cells. The 
ectocervix and the transformation zone are more biased towards cytotoxic T-lymphocyte 
response whereas the endocervical tissue mediates humoral responses due to a high amount 
of plasma cells [181, 182]. These plasma immune cells express a variety of TLRs, allowing 
them to recognize the different repertoire of a wide range of PAMPs [183-185]. The 
menstrual cycle also affects the immune system of the cervix and it has been suggested that 
female sex hormones are primary responsible for the antibody concentration in the cervix 
[186-188]. To ensure a healthy microenvironment while still allowing the mucosal tissue to 
fulfill its role as a barrier, the mucosal immune system has developed a remarkable balance. 
In this regard the FGT has to be tolerant to sperms and the implementation of the fetus to 
ensure pregnancy, while on the other hand it combats STIs targeting the FGT [189]. 
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Cervical immune response to HPV   
The squamous epithelium of the cervix is subdivided into two distinct regions, the epidermis 
and the dermis, separated by the epidermal basement membrane. The squamous epithelium 
of the cervix is populated with an array of immune cells [190, 191]. Keratinocytes (KCs) 
constitute the majority of the cells of the squamous epidermis while the majority of immune 
cells are located in the dermis [192]. Even if KCs are not considered as classical immune cells, 
they have some immune functions and can act as APCs. They can also secrete 
proinflammatory cytokines and chemokines. Langerhans cells (LCs) together with dendritic 
cells (DCs) constitute the majority of the immune cells in the dermis [193]. HPV infects only 
the epidermal cells of the cervical mucosa, without penetrating into the dermal tissue. Even if 
infections may persist for months or years, in the majority of cases, immunity-based 
regression of HPV lesions does finally occur [194-196]. The dsDNA and L1-L2 capsid 
components of the HPV virions are potential PAMPs that can trigger TLRs [183]. Studies 
showed that up-regulation of TL3, TLR7, TLR8 and TLR9 occurred in women where HPV16 
infections were cleared [197]. Other studies have shown that up-regulation of TLR9 is 
associated with HPV persistence [198]. In cervical cancer, a down-regulation of TLR1, TLR3 
and TLR5 and up-regulation of TLR2 compared to the controls was demonstrated [199]. In 
addition, studies suggest that a Th1 immune response favors clearance of cervical HPV 
infection [200], while a Th2 immune response favors progression to cervical cancer [201, 
202].  
1.4.2 Mechanism involved in HPV escape from the immune 
system and development of cervical cancer 
Perturbation of antigen processing and presenting  
In general, the immune system is able to destroy HPV and eliminate infected cervical 
epithelial cells. However, but about 10% of HPV infections leads to cervical lesions due to a 
failure of the immune response [203]. Host defense against viral infections is a collaboration 
between the innate immunity and the adaptive immunity [190]. HPV possesses mechanisms 
to evade the host’s immune response and it is thought that the virus manipulates various 
molecular and cellular pathways in the host cell to evade host immune surveillance and 
antiviral immune responses [190].  
KCs are the major cell type in the epidermis and have some immune functions such as 
secreting cytokines [192]. The compromised innate immune defense in KCs is an important 
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reason for the evasion of the HR-HPV infection from the immune response, eventually 
resulting in a persistent HPV infection and the development of precancerous lesions. The 
infectious cycle of HPV is itself an immune evasion mechanism inhibiting host detection of 
the virus [25, 204]. The first mechanism that HPV uses resides in the fact that it only causes 
neoplasia to a particular site where vulnerable KC cells are found [190, 205]. In addition the 
virus targets KC cells, constituting sentinels of the host defense [205, 206]. The E5 HPV 
oncoprotein plays a key role in cell growth and impairs several signal transduction pathways 
of the host [207]. It has been shown that the antigen processing by major histocompatibility 
complex (MHC) I [190] constitutes the major immune mechanism disrupted by HPV. In this 
process, HPV disrupts MHC I expression in a variant-selective manner to protect infected cell 
against NK and CTL cytotoxicity [30, 190].  
The detection by the innate immune response of PAMPs is an important feature of the 
immune system [205]. To avoid this detection, HPV infection targets only epithelial cells and 
viral replication happens outside the basement membrane and distant from the resident 
dermal immune effectors [205]. In addition, in the normal case the viral oncoproteins E5, E6 
and E7 are detected by the immune system [30], however, for most of HR-HPVs the 
expression of these oncoproteins happens in KC of the upper layer of the epithelium where 
the immune system has limited access [205]. HPV is also a purely intraepithelial pathogen 
and its life cycle is coupled to the cycle of differentiating KC [25, 204]. The lack of damage to 
host cells ensures a minimal immune response. Little or no release of proinflammatory 
cytokines is induced in HPV infection [31]. Studies show that oncoproteins E6 and E7 interfere 
with the expression of proinflammatory cytokines and chemokines [25, 204]. E6 and E7 are 
also known to directly interfere with TLR9 mediating pathways [29] and reduce the 
expression of proinflammatory cytokines. 
Interaction with host Th1/Th2 phenotypes 
HPV has been shown to induce a shift from a Th1 (known as cellular response) to a Th2 
response  (known as humoral response) [200, 208]. Furthermore, type I IFNs are produced by 
most of cells in response to viral infection in both infected and neighbor cells besides 
participating in the activation of adaptive responses by the innate immunity [209]. E6 and E7 
genes may interact directly in altering the immune response against infected cells by 
suppressing IFN expression and signaling pathways [30]. Moreover, HR-HPV infection has also 
been shown to induce regulatory T cell (Treg) [208]. This HPV-mediated immune suppression 
during virus persistence may contribute to tumor cell evasion of antitumor immune 
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responses expression [30] . E5 may be involved in the inhibition of cytotoxic T cell function 
locally [25, 204].  
1.5 Prevention of HPV infection and cervical cancer 
Cervical cancer is particularly amenable to prevention as it has a long preclinical phase and 
the natural history of cervical carcinogenesis is well researched [44, 81, 208]. Cervical cancer 
prevention requires multidimensional approach involving primary, secondary and tertiary 
prevention [210]. Primary prevention aims to reduce the incidence of a disease within a 
population. It involves interventions that are applied before there is any evidence of disease. 
The aim of secondary prevention is to detect a disease in its earliest stages of development, 
before symptoms appear, and to stop its progression with lighter treatment methods leading 
to a greater chance of recovery. Tertiary prevention primarily aims to prevent or control the 
morbidity caused by cancer therapy, but it also encompasses the prevention of cancer 
recurrence.  
1.5.1 Primary prevention 
 In terms of cervical cancer, primary prevention includes population education about cervical 
cancer and HPV vaccination. 
Mass education 
Although HPV is the most prevalent sexually transmitted infection in worldwide, public 
knowledge and awareness about cancer continue to be at poor level [211, 212]. A study was 
designed to examine the knowledge and beliefs about HPV among college students in 
Vietnam compared to college students in the US. On average, both Vietnamese and US 
participants could correctly answer less than half of the survey questions regarding HPV 
knowledge [213] . Studies of university students and employees in England report that many 
women underestimate the likelihood of receiving abnormal Pap test results [214, 215]. In 
addition, one of the main reasons for the high cancer mortality in sub-Saharan Africa is poor 
public knowledge and awareness about cancer. Poor cancer awareness and knowledge 
among primary health-care providers in sub-Saharan Africa has also been documented [216, 
217], which negatively affects accurate diagnosis at the primary care level and causes delays 
in referrals to specialists, and late diagnosis [218]. Cancer awareness is important to improve 
risk reduction behaviours, promote timely cancer screening for early detection, and 
ultimately reduce the cancer burden in sub-Saharan Africa [211, 219, 220]. 
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Vaccination 
Vaccines against cervical cancer can be divided into two groups, the prophylactic and the 
therapeutic vaccines.  
a) Prophylactic vaccines 
Prophylactic vaccines contain HPV L1 self-assembling virus-like particles that induce strong 
neutralizing antibody responses against HPV infections. These antibodies are thought to block 
the HPV virions before they gain access to the proliferating basal cell layer of the epithelial 
surface through micro-abrasions [221]. There are currently three prophylactic HPV vaccines 
[222], i.e., a bivalent vaccine targeting HPV16 and HPV18 (Cervarix
®
), a quadrivalent vaccine 
(Gardasil
®
) targeting HPV16 and HPV18 and HPV6 and HPV11 that cause genital warts and a 
nonavalent vaccine (Gardasil 9
®
) which has been licensed recently in the USA, Europe, and 
other high income countries .It targets also additional oncogenic HPV serotypes: HPV31, 33, 
45, 52 and HPV58 [223]. There is good evidence that prophylactic HPV vaccines are 
immunogenic and effective against targeted-type HPV infections and cervical lesions when 
administered prior to HPV infection [224-226]. In addition, evidence supports that HPV 
vaccines are safe and there is good evidence for some cross-protection against non-targeted 
types occurring following the administration of HPV vaccines [227]. By the year 2014, 58 
countries introduced HPV vaccination in their national immunization program [228]. 
Countries that implemented HPV vaccination before 2010 have already experienced a 
decrease in population prevalence in targeted HPV genotypes [229, 230]. Studies show a 
reduction in the prevalence of abnormal cervical cytology due to HPV vaccination [231, 232]. 
Importantly, after more than 100 million doses given worldwide, HPV vaccination has 
demonstrated an excellent safety profile [233]. Rwanda was the first African country to 
implement a national vaccination program against HPV [3]. In 2011, over 92,000 girls in 
primary school grade six were vaccinated with the quadrivalent vaccine, Gardasil
®
 [3]. The 
three-dose vaccination coverage was estimated at 93% in the target population [3]. During 
the period 2012 and 2013, despite being heavily criticized [234, 235], a catch-up vaccination 
program targeting girls 15 years old was also initiated [236].  
Therapeutic vaccines 
Therapeutic vaccines targeting E6 and E7 along with broadly targeting immunotherapies or 
peptides are in clinical development. The rationale of these vaccines is to avoid the need for 
surgical procedures by developing immune responses against HPV [237]. Clinical trials have 
been moderately successful in eliciting cell-mediated immune responses to E6 and E7 in 
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patients; however, clinical responses have not been consistent [238-240].  
1.5.2 Secondary prevention 
Secondary prevention includes screening asymptomatic patients (primary screening) or 
screen positive patients to detect precancerous lesions (triage) before they turn into cancer 
[241]. The primary goal of cervical cancer screening is the accurate detection and timely 
treatment of intraepithelial precursor lesions of the cervix at a population level for the 
purpose of cervical cancer prevention rather than cancer control [242]. Therefore the long 
process of carcinogenic transformation from HPV infection to invasive cancer provides ample 
opportunities to detect the disease at a stage when treatment is highly effective [241]. High-
quality screening programs can lower the incidence of cervical cancer by up to 80% [243]. The 
introduction of regular cervical cancer screening program is anticipated to lead to a fall in the 
incidence of invasive cervical cancer cases and deaths [242]. The mean age at the detection 
of CIN 2 is 35 and that of CIN 3 is 40 years. Hence, the possibility of detecting high-grade 
lesions is highest if the women are screened between 35 and 45 years of age [244]. Invasive 
cancers are rare before the age of 30 years, and screening women too young leads to the 
detection and unnecessary treatment of spontaneously regressing low-grade lesions [245]. 
Based on such evidence, the World Health Organization (WHO) recommended initiation of 
screening at the age of 30 years in developing countries [246]. All sexually active HIV-infected 
women however, should be screened for cervical cancer immediately after their HIV status is 
known because of the aggressive nature of cervical neoplastic process in HIV positive women 
[242, 247]. 
A number of different methods are available for cervical cancer screening. In some screening 
programs, cytology (both conventional and liquid-based) is the primary screening mode.  In 
others, cytology is combined with HPV DNA testing (co-testing). Some countries and regions 
are moving toward or have adopted primary HPV DNA testing or visual inspection with acetic 
acid (VIA) [248]. Other modalities such as direct visual inspection (DVI), visual inspection 
using acetic acid and magnification (VIAM); visual inspection using Lugol’s iodine (VILI) can be 
used for further evaluation of abnormal results [249]. 
Conventional Cytology 
The primary method for detection of cervical cancer is still the Papanicolaou-stained (Pap) 
smear. The Pap smear is a screening tool that detects changes in cells of the transformation 
zone of the cervix [250]. Liquid-based cytology is an improved form of cytology. It has 
practical advantages since cytology and HPV testing can be done on the same sample. The 
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reporting system of Pap smear results has evolved and been refined over time. The current 
reporting system is the Bethesda System, 2014 [251]. In this system, the smear is reported as 
negative for intraepithelial lesion or malignancy; atypical squamous cells of undetermined 
significance (ASCUS); atypical squamous cells, cannot exclude high grade lesion (ASC-H); LSIL; 
HSIL; squamous cell carcinoma; atypical glandular cells (ACG); adenocarcinoma in situ (AIS); 
or adenocarcinoma. Other reporting systems exist (Fig. 6).  
Figure 6.Terminology of cervical diseases categories [252]. The figure shows histological and cytological 
terminologies of cervical disease categories. CIN [253]; LAST [244, 254]; NILM, negative for intraepithelial 
lesion or malignancy [255]. 
HPV test 
The commercially available HPV tests detect either the viral DNA or the messenger 
ribonucleic acid (mRNA) of the E6 and E7 oncoproteins of the most oncogenic HPV types. The 
introduction of HPV testing in primary cervical cancer screening was initiated as a response to 
the low sensitivity of cytology test [256]. In fact many clinical trial and comparatives studies 
conducted in Europe confirmed high sensitivity of HPV testing in detecting high-grade lesion 
than cytology (95% versus 55%), and found that it had a slightly lower specificity (94% versus 
97%) [257, 258]. In India, Sankaranarayanan et al., (2009) showed a significant reduction in 
cervical cancer mortality associated with a single HPV test in comparison to a single cytology 
test [259]. This observation was supported by other studies [260-262]. Because of the inferior 
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specificity of HPV tests, a second test may be done on the HPV-positive women (triaging test) 
to identify those who are at higher risk of progressing to the disease and thereby only 
referring those positive on both tests to colposcopy. Combining the high sensitivity of HPV 
DNA test and the high specificity of cytology can increase the screening interval for testing in 
women negative by both methods [249]. Recently, HPV testing with cytology was introduced 
as an alternative to cytology screening in most of the countries following a Food and Drug 
Administration (FDA) approved use of HPV test in association with cytology [258, 263]. 
Cytology as a primary screening method is less sensitive than HPV testing [264]. However 
combining the high sensitivity from HPV DNA testing with the high specificity of cytology can 
increase the screening interval for women being negative for both methods [265]. 
Visual inspection with acetic acid (VIA) testing 
The principle of VIA test bases on the fact that the neoplastic lesions of the cervix become 
white after application of 3-5% acetic acid for 1 min and the density and characteristics of 
aceto-whitening depend on the severity of the lesion. However, the VIA test is associated 
with a high level of subjectivity [266] and it has a low sensitivity especially in postmenopausal 
women [267].  
In Rwanda, there is no systematic screening program implemented yet but at occasion, VIA 
and colposcopy services are currently provided at four referral hospitals and four district 
hospitals. Only two pathologists located in Kigali and Butare service the entire country [236, 
268]. In addition many women consult in late stages and for numerous reasons [269] 
1.6 Radiotherapy-induced adverse effects in normal 
tissue  
While earlier stages of cervical cancer are treated with surgery, advanced stages are often 
treated with radiotherapy alone or in combination with chemotherapy. Despite advances in 
dose planning in radiotherapy, healthy tissue surrounding the tumour is still included in the 
radiation field and radiation-induced injuries may arise [270]. Cervical cancer patients treated 
by radiotherapy may be affected by acute and late radiation-related toxicity in 51% and 14% 
of cases, respectively [271]. Some of consequences of radiotherapy are radiation-induced 
cystitis, proctitis and ureteral stenosis [272-274]. Radiotherapy may also lead to structural 
and morphological changes in the FGT affecting sex life negatively [275, 276]. In addition, 
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cases of cervical necrosis (1.76%) had been reported among cervical cancer patients three to 
four months following radiotherpy [277]. 
Radiation induces oxidative stress and immune responses in normal tissue 
Radiotherapy leads to an increase in reactive oxygen species (ROS) leading to oxidative stress 
[278]. Increased ROS may lead to apoptosis due to cytochrome c and caspase activation in 
mitochondria [279]. Nuclear factor erythroid 2–related factor 2 (Nrf2) is a transcription factor 
encoding antioxidant genes including heme oxygenase 1 (HO-1) and protects the cell against 
oxidative stress induced by radiation [280, 281]. Accumulation of extracellular matrix leading 
to the development of fibrosis may take place in normal tissue exposed to radiation and 
oxidative stress [282]. Besides oxidative stress, TGFβ is a key player in the development of 
fibrosis [283, 284]. Inhibition of TGFβ has been shown to attenuate the development of 
radiation-induced pulmonary fibrosis [285]. Treatment with antioxidants may also reduce 
levels of TGFβ and lead to decreased radiation-induced lung injuries [286].  
Radiation also activates the innate immune response, which as a consequence lead to the 
release of cytokines and inflammation [278, 287, 288].  Previous studies show that the 
immune system is changed following irradiation of the lung [289], the colon [290], and the 
urinary bladder [291]. TLRs are down regulated in the urinary bladder and in macrophages in 
response to irradiation [291, 292]. Stimulation with agonists targeting TLR4 and TLR5 may 
abrogate immunological changes induced by colorectal irradiation of the rat [293].  
Radiotherapy induces damage in epithelia, microvasculature and nerves 
Radiation may affect crypts and lead to disruption of the barrier function of the colon [294, 
295], which in some cases may lead to severe diarrhea [296]. Although Nrf2 in most tissues 
generates radioresistance [280], Nrf2-knockout mice were shown to be less sensitive to 
abdominal radiation than wild-type mice [297]. Radiation leads to damage of microvessels in 
the intestines [298]. Cardiac exposure to radiation may lead to dysfunction of microvascular 
endothelial cells [299]. In animal models for radiation cystitis, radiation may lead to changes 
in the neuronal control of the urinary bladder leading to urinary frequency [300, 301], a 
symptom pathognomonic for radiation cystitis [302]. Moreover, changes have been 
demonstrated in the density of nerves in the urinary bladder in an animal model for radiation 
cystitis [303]. Pudendal nerve dysfunction may also develop after brachytherapy against 
prostate cancer [304].  
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Radiotherapy-induced adverse effect of the FGT 
Cervical cancer patients undergoing radiotherapy develop often radiotherapy-induced 
adverse effects of the FGT of various degrees of severity [305]. These women often report 
vaginal dryness, reduced vaginal dimension and dyspareunia [306]. Studies show that vaginal 
fibrosis and elastosis may develop in women undergoing pelvic radiotherapy [276]. Sexual 
dysfunction in gynecological cancer survivors may have severe impact on quality of life [307]. 
There is a scarcity in effective therapeutic alternatives for this patient group and few studies 
have been conducted in this research field [307].  
HBOT in the treatment of adverse effects to radiotherapy 
Hyperbaric oxygen therapy (HBOT) is a treatment where patients are exposed to oxygen at 
pressures higher than atmospheric pressure at sea level [308]. The treatment is the standard 
of care for decompression sickness [309], however, today other medical conditions in 
patients undergoing HBOT dominate. HBOT increases the oxygen tension in tissue and is 
effective in the treatment of chronic ulcers [310, 311]. HBOT stimulates angiogenesis as 
demonstrated in patients undergoing HBOT due to exposure to irradiation of the buccal 
mucosa [312]. Animal models also show that HBOT increases the microvessel density of the 
penumbra after ischemic stroke [313]. Besides chronic ulcers, HBOT is effective against 
carbon monoxide poisoning [314]. HBOT is an important treatment option also for radiation 
cystitis and proctitis [272]. The exact mechanisms by which HBOT alleviates symptoms 
associated with radiation-induced cystitis and proctitis are unknown. In an animal model for 
radiation cystitis, immunological and oxidative changes were reversed by HBOT [315]. 
Whether HBOT is also effective in the therapy of radiation-induced adverse effects of the FGT 
is not known due to a very limited number of studies conducted in this research field. A 
prospective study in women treated for gynecological malignancy with late adverse tissue 
injuries, failed to show any alleviating effects in pain after HBOT [316]. Other studies suggest 
that the treatment is effective in women developing vaginal ulcers and fistula after 
radiotherapy [317].  
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2 STATEMENT OF THE PROBLEM AND STUDY 
JUSTIFICATION  
Cervical cancer is a very important health issue in Rwanda contributing to a high morbidity 
and mortality in the country. The following are some of limitations identified in Rwanda: 
A. In Rwanda there is a known scarcity in national epidemiological data on cervical cancer. 
The only few studies available were conducted in Kigali, the capital and only describe cervical 
cancer among HIV infected women. This was because not only HIV infection was regarded as 
a public health problem for women but also because most of the Rwandan health sector 
partners targeted mainly HIV/AIDS prevention. 
B. Rwanda is among few African countries that have introduced large-scaled HPV vaccination 
programs. Many studies conducted in Africa demonstrated that the currently used vaccines 
do not target the most common HPV genotypes. Whether the currently used vaccine in 
Rwanda gives protection against HPV infections in the country has not been studied.  
C. The recommendation is that girls should be vaccinated before the onset of their sexual 
activities; however, no studies have been performed in Rwanda assessing the age of sexual 
debut among women. 
D. No cervical cancer-screening program is provided for the general female population in 
Rwanda.  
E. Cervical cancer patients referred for radiotherapy in Uganda are generally not followed up 
and there are no studies on the extent of side effects related to radiotherapy among these 
patients. 
F. In combining all these persisting issues for an effective cervical cancer control in Rwanda 
we conclude that there is a need of a more complete understanding of the natural history of 
HPV infection and cervical abnormalities. 
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3 AIMS 
3.1 General aims 
The overall objectives of the study were to assess the prevalence and the natural history of 
HPV infections in Rwanda, the contributions of STIs and other risk factors and how the 
immune system of the cervix responds to inflammatory stimuli.  
3.2 Specific aims 
3.2.1 Clinical studies (Paper I-III) 
 To determine the prevalence of HPV infections and related cytological 
abnormalities among HIV+ and HIV- Rwandan women. 
 To assess whether HPV test could work as a screening method for detecting HSIL 
and worse cytology. 
 To describe the prevalence and risk factors for STIs/RTIs in HIV+ and HIV- Rwandan 
women. 
 To assess the effect of sexual behaviour on the awareness of HIV positivity and 
present STIs in HIV+ and HIV- Rwandan women. 
 To identify risk factors associated with HR-HPV persistence and those associated 
with cytological abnormalities in HIV+ and HIV- Rwandan women. 
 To identify risk factors for LSIL and HSIL/cancer in HIV+ and HIV- Rwandan women. 
 To determine whether IL28B SNP rs12979860 correlates with HPV susceptibility and 
HPV persistence and development of HSIL  
3.2.2 Preclinical studies (Paper IV-V) 
 To explore the effect of a single high dose of ionizing radiation on cervical immune 
system in rat model.  
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 To evaluate the effect of HBOT on rat cervical tissues following high dose of 
radiation treatment. 
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4 METHODS 
4.1 Clinical studies (paper I-III) 
4.1.1 Study design  
Paper I was a cross-sectional study on the prevalence of HPV and SIL in Rwandan women. 
Paper II and paper III were prospective cohort studies following identified HPV positive 
women and women with abnormal cytology and an age-matched control group from paper I. 
Women were followed for 9 months (paper II) and for 24 months (paper III). After obtaining 
the informed consent from all study participants, women meeting inclusion criteria were 
enrolled to the studies. 
4.1.2 Study area 
Women participating in the studies were recruited between July 2015 and October 2017. HIV 
positive women were recruited at the HIV clinic at the University Teaching Hospital of Kigali 
(CHUK; HIV positive group). Participants were also recruited at the Department of 
Obstetrics and Gynecology at CHUK and at the University Teaching Hospital of Butare (CHUB). 
Women were tested for HIV and if being tested negative referred to the HIV negative group 
and if being tested positive referred to the HIV positive group. While CHUB is the referral 
hospital for the southern region of Rwanda, CHUK, situated in Kigali in the middle of Rwanda, 
is the referral hospital for most of the rest of the country. 
4.1.3 Study population 
All women aged between 17 years and older visiting the gynecology and obstetrics 
department at CHUB or CHUK and all HIV-infected women followed at HIV clinics at internal 
medicine at CHUK were invited to take part in the study. Inclusion criteria were the following: 
women seeking voluntary for cervical cancer screening service, who were 17 years old or 
older, who were literate in either Kinyarwanda, English or French, who had filled and signed 
the Informed Consent Form and who did not had plans to relocate in the next two years. 
Exclusion criteria were present pregnancy, a history of HPV infection and/or cervical cancer 
and presenting any known concurrent disease likely to limit life expectancy to less than 24 
months or presenting any other factor suggesting inability to comply with the study protocol. 
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4.1.4 Sampling and sample size 
A non-proportional quota sampling was applied to enroll participants to our study. For paper 
I, two hundred women in each one of the two cohorts were recruited to assure analysis even 
for small subgroups in the population. All participants in different cohorts were continuously 
recruited until the desired number was reached. At baseline, 119 women tested positive and 
or with cervical cytology abnormalities (referred as cases), regardless of their HIV status, 
were included in the study. Then 118 women tested to be HPV negative with normal cervical 
cytology test and age-matched to cases were purposely selected to constitute the control 
group.  
4.1.5 Study procedures 
Procedures at enrolment and follow-up 
A nurse or physician at each concerned health facility received women at daily basis and 
reviewed if the women met the requirements to participate in the study. When inclusion 
criteria were met, the patient was informed about the study orally and by written 
information. After the informed consent form was signed, a face-to-face interview was 
conducted by after what the women were examined by a physician and samples were taken 
(see below). Women underwent a new interview at 9 months (paper II). Women were called 
back for cervical samplings 9 months, 18 months and 24 months after inclusion in the study.  
4.1.6 Data collection 
Interview and analysis of patients’ medical records 
A standardized questionnaire was administered to participants in the study at baseline and at 
9 months. Data collected during interviews covered demographics (age, years of schooling 
and marital status), reproductive history (number of live births, number of abortions, 
hormonal contraceptive and intrauterine device use) and sexual activity (age at first 
intercourse, number of sexual partners). History of sexually transmitted infections 
(chlamydia, gonorrhea), medical history (cervical cancer screening test, HIV status) and 
smoking (past or current) were also part of the questionnaire. At 9 months, a short 
questionnaire covering information on sexual activity, number of new sexual partners and 
condom use during the last 9 months was used. Data on CD4 counts, viral load and 
antiretroviral therapy (ART) were found in the medical record of the patients.  
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Cytology and HPV screening 
At each clinical examination, a cytobrush (Hologic, Inc., Marlborough, USA) was inserted 
through a speculum and rotated in the cervical canal.
 
The collected cells were then agitated 
into 20 ml of PreservCyt solution (Hologic, Inc.) and stored at room temperature till the 
transport to Sweden for further processing and analysis. Once in Sweden, 2 ml of each 
sample were sent to the Laboratory of Infectious Epidemiology, Department of Laboratory 
Medicine, the Karolinska Institute, Stockholm, Sweden, for HPV DNA and genotyping. HPV 
DNA analysis was performed by the use of the Multiplex Luminex system (Bio-Rad 
Laboratories, Inc., Irvine, CA, USA). Forty different HPV strains were analysed organised as 
follow: low-risk LR-HPV: 6, 11, 30, 40, 42, 43, 54, 61, 67, 73, 74, 81, 82, 83, 86, 87, 89, 90, 91; 
high-risk HR-HPV: 16, 18, 18v, 31, 33, 35, 35v, 39, 45, 51, 52, 56, 58, 59, and possibly high-risk 
(PHR)-HPV 26, 53, 66, 68a, 68b, 69, 70. The rest of the specimens were sent to the Cytology 
and Pathology Department, Sahlgrenska University hospital, Gothenburg, Sweden, for 
Thinprep Pap test. Liquid-based cytology was prepared and performed according to the 
manufacturer’s instructions on PreservCyt samples, using the fully automatic ThinPrep 5000 
System (Hologic, Inc.) followed by Pap staining (Hologic, Inc.). All slides results were read and 
interpreted by a cytologist at the lab. In case of HSIL or invasive cancer suspicion, a 
pathologist reviewed slide also. All cytology results were reported according to the Bethesda 
2001 system as: Normal, Not Determined, ASCUS, AGUS, ASC-H, LSIL, HSIL, AIS and cancer. 
SNP analysis was also performed on the cytology solution (see below).  
 Testing for STI and RTIs  
At baseline and at nine months, a vaginal swab for bacterial vaginosis, candidiasis and 
trichomoniasis was collected. At the same time, a blood sample was also taken for HIV (for 
non-HIV+ cohorts), Treponema pallidum (syphilis), hepatitis B (HBV) at the CHUK and CHUB 
clinical laboratories by well-trained laboratory technicians.  
HIV testing 
In brief, serum specimens were first screened by the use of Alere HIV Combo (Alere Medical 
Co., Ltd, Chiba, Japan), and then reactive samples were confirmed by the second test, HIV ½ 
Stat- Pak
®
 (Chembio Diagnostic System, Inc. New York, USA). Reactive samples were finally 
reported as positive.  
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Syphilis, HBV and HCV testing 
Testing for syphilis was conducted using the rapid plasma reagin (RPR) test (Macro-Vue RPR 
Card Test, BD, USA). The RPR-positive samples were sent to the National Reference Laboratory 
within 24 hours for confirmation using the Treponema pallidum haemagglutination (TPHA) 
test, the rapid test to detect syphilis antibodies. A sample that was positive for both tests was 
recorded as positive and a non-reacting sample to the second test was recorded as negative. 
The Screening for HBV was performed using the HBsAg Rapid Test Strip (Rapid Labs 
Ltd, Colchester, United Kingdom) to detect HBV surface antigen (HBsAg). A reacting 
sample was recorded as positive. HCV testing was performed using the HCV Rapid Test 
Strip (Rapid Labs Ltd, Colchester, United Kingdom). The test detected HCV antibodies 
(anti-HCV). A reactive sample was recorded as positive. All rapid tests were performed and 
interpreted according to the manufacture’s recommendations. 
Testing for candidiasis, trichomoniasis and bacterial vaginosis  
Cervicovaginal samples were cultured on Sabouraud culture medium for detection of 
candidiasis.  The identity of clinical isolates was confirmed by germ tube induction test 
in serum for Candida albicans. Trichomoniasis was diagnosed by wet mounts evaluation 
and examined microscopically within 15 min for motile Trichomonas vaginalis 
identification. Bacterial vaginosis was diagnosed by the presence of three of the clinical 
and microscopic findings on Gram stain, standardized by Nugent scoring method [318]. 
SNP analysis 
From the cervical sample solution, the IFNL3 SNP for IL28B rs12979860 polymorphism was 
determined by using TaqMan
 
SNP Genotyping Assays (Applied Biosystems (ABI), Carlsbad, 
California, USA). Each genomic DNA (2μl) contained in cervical samples, in PreservCyt 
transport medium (Hologic Inc.), was amplified with TaqMan genotyping Master mix reagent 
(ABI) combined with TaqMan SNP genotyping primers and probes (FAM and VIC) (ABI). The 
real time polymerase chain reaction (RT-PCR) reactions were performed using 7500 Fast RT-
PCR Systems and following standard mode of thermal cycling conditions. Automatic call 
decisions were made with the SDS software for the allelic discrimination. 
Data Management 
All collected data have been managed in accordance with the International Conference of 
Harmonization (ICH) guidelines, and data management principles. The data management 
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routines included procedures for handling Case Report Forms (CRFs), database set-up and 
management, data entry and verification, data validation, and documentation of the 
performed activities including information of discrepancies in the process. All the data in the 
CRFs were subject to both visual checks and computer-driven procedures. Data were stored 
on a computer with a login that was only accessible for the investigators and personnel 
within the project. The database and the data entry screens were designed in accordance 
with the study protocol and the CRF. Data validation and check out were performed after 
data entry and verification by manual review. Data from patients were coded so participant 
could not be identified.  
4.1.7 Data analysis and statistics 
Statistical analysis was performed with the use of IBM SPSS 22 & 25 versions and Graph Pad 
Prism 6 and 7 versions. Descriptive statistics were done wherever appropriate to describe 
baseline characteristics of participants. All statistical tests were two-sided and considered 
significant when p-values were <0.05. Depending on the sample size we used the chi-square 
test or the Fisher’s exact test to compare categorical data. Univariate logistic regression 
analysis was performed and odds ratios (ORs) with 95% confidence intervals (CIs) were 
calculated. Variables with a univariate p-value of <0.05 (paper I) or a p-value of <0.2 (paper II) 
were entered in the multivariate logistic regression analysis by the enter method and 
adjusted odds ratios (AORs) were then determined.  
In paper II, PHR-HPV and HR-HPV were grouped into one category denoted HR-HPV. Kaplan-
Meier curves were created for HR-HPV and LR-HPV persistence and the log-rank test was 
performed to compare Kaplan-Meier curves. The percentage of incidentally infected (HR-HPV 
or LR-HPV) women at 9-24 months who were HPV negative at baseline divided with the 
number of women at risk was calculated to give the cumulative incidence. Incident HPV 
infections were considered as HPV infections not present at baseline but present at any time 
point 9-24 months. Positive test results for the same PHR/HR-HPV type at three consecutive 
time points or two non-consecutive time points separated with a negative test result were 
considered type-specific HR-HPV persistent infections. Type-specific persistence was also 
considered in the case of two consecutive HPV positive results followed by missing data. HPV 
clearance was considered in a situation when a HPV positive test was followed by at least two 
negative tests or one positive test followed by one negative test followed by missing data or 
no more sampling occasions. In the statistical analyses, women infected only with LR-HPV(s) 
were considered LR-HPV infected, while women infected by HR- or PHR-HPV(s) were 
considered HR-HPV infected. Women infected by LR-HPV(s) and HR/PHR-HPV(s) were 
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considered HR-HPV infected. Women with unsatisfactory results (not determined) were 
considered as abnormal in the statistical analyses. In case one cytology sample was evaluated 
as not determinable and the other samples were evaluated normal the woman was 
considered to have normal cytology. 
In paper III, syphilis, trichomoniasis, hepatitis B and hepatitis C were considered STIs, while 
bacterial vaginosis and candidiasis were considered RTIs. Since the number of individual RTI 
and STI cases was low, statistics were performed on the STIs and RTIs group level. PHR and 
HR-HPV infections were also grouped in one category denoted HR-HPV.  
4.2 Preclinical studies (paper IV-V) 
4.2.1 Animals 
Sprague-Dawley female rats (200–250 g; CD
®
 IGS rat, Charles River, Germany) were housed in 
a temperature-controlled facility with a day and night cycle, and had free access to food and 
water ad libitum. In paper IV, rats were either irradiated or only sedated (controls) and 
irradiated rats were either euthanized at 1 day, 3, 7 or 14 days after cervical irradiation. In 
paper V, rats were assigned to four groups, i.e., irradiated, irradiated + HBOT, HBOT g or 
control group (neither irradiation nor HBOT).  All rats were euthanized 28 days after cervical 
irradiation (or sedation for control group). 
4.2.2 Irradiation of uterine cervix 
On the day of cervical irradiation, rats were sedated with pentobarbitone (50 mg/kg) im and 
medetomidine (10 µG/kg) ip. Rats were placed in the supine position and the uterine cervix 
was then irradiated with one fraction of 20 Gy given by a linear accelerator (Varian Medical 
Systems Inc., Palo Alto; 6 MV). Radiation was given in two side-fields to minimize the 
exposure of the spinal cord. Rats had food and water ad libitum and were sacrificed by an 
overdose of anesthetics 1, 3, 7 and 14 days (paper IV) or 28 days (paper V) after irradiation of 
the uterine cervix.  
4.2.3 HBOT 
HBOT was given in a hyperbaric chamber (GDA Sverige AB, Gothenburg, Sweden). In the 
chamber, rats were exposed to 100% oxygen pressurized to 200 kPa for 90 minutes twice 
daily, Monday-Friday for a total of 20 sessions given over two weeks. Control rats, (no 
irradiation, no HBOT), were sedated on day 1 and then kept in their cages for 28 days. HBO 
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control rats (no irradiation, HBOT) were sedated and then kept in their cages for 14 days 
before receiving 20 sessions of HBOT over a period of 14 days. Irradiated rats (radiation, no 
HBOT) were sedated and irradiated on day 1 and were kept in their cages for 28 days. HBO 
irradiated rats (radiation, HBOT) were sedated and irradiated on day 1, kept in their cages for 
14 days before receiving 20 sessions of HBOT over a period of 14 days.  
4.2.4 Collection of cervical specimens  
After euthanization of the rat, the uterine cervix was excised and cut into two sagittal parts 
where one part was frozen to -70
 o
C degrees for late protein extraction for western blot and 
cytokine analysis whereas the other part was put in formalin for paraffin embedding.  
4.2.5 Antibodies 
List of primary antibodies (immunohistochemistry (IHC)/western blot (WB)) 
Mouse anti-β-actin (WB 1:2000, Santa Cruz Biotechnology (SCBT), Santa Cruz, CA, USA, sc-
47778), mouse anti-catalase (IHC 1:100/WB 1:500, SCBT, sc-271803), mouse anti-8-OHdG 
(IHC 1:2000, Abcam, ab62623), mouse anti-SOD-2 (IHC 1:50, SCBT, sc-137254), mouse anti–
TLR9 (WB 1:500, Sigma Aldrich, WH0054106M3), mouse anti-α-tubulin  (WB 1:2500, Abcam, 
T9026), rabbit anti-MyD88 (IHC 1:100, SCBT, sc-11356, WB 1:200, Abcam ab2064), rabbit 
anti-NFκβ (WB 1:1000, Abcam, ab86299), rabbit anti-SOD1 (IHC 1:1000/WB 1:50000, SCBT, 
sc-11407), rabbit anti-SOD-2 (WB 1:1.500, Abcam, GR3318-56), rabbit anti-TLR1 (IHC 
1:100/WB 1:250, SCBT, sc-30000), rabbit anti-TLR2 (IHC 1:100/WB 1:500, SCBT, sc-10739), 
rabbit anti-TLR3 (IHC 1:100/WB 1:500, SCBT, sc-28999), rabbit anti-TLR-4 (IHC 1:100/WB 
1:500, SCBT, sc-30002), rabbit anti-TLR5 (IHC 1:100/WB 1:500, SCBT, sc-30003), rabbit anti-
TLR6 (IHC 1:100/WB 1:500, SCBT, sc-30001), rabbit anti-TLR7 (IHC 1:100/WB 1:500, SCBT, sc-
30004), rabbit anti-TLR8 (IHC 1:100/WB 1:500, SCBT, sc-25467), rabbit anti-TLR9 (IHC 1:100, 
SCBT, sc-25468) and rabbit anti-TRIF (IHC 1:500/WB 1:1000, Thermo Fisher Scientific, PA5-
23467). 
List of secondary antibodies  
Alexa Fluor
 
488 goat anti-rabbit IgG (H+L)*2 mg⁄mL (IHC 1:250, Life Technologies, A11008), 
goat anti-mouse IgG (H+L)-HRP (WB 1:4000, Thermo Fisher Scientific, SA248187), goat anti-
rabbit IgG-HRP (WB 1:5000, Abcam, ab 6721) and Texas red goat anti mouse IgG (H+L) (IHC 
1:250, Life Technologies, T862). 
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4.2.6 Western blotting  
Cervix tissue specimens were homogenized using homogenization buffer. Homogenates were 
then centrifuged at 10000g for 15 min at 4
o
C. The total protein concentration in the 
homogenate was measured using the Pierce BCA Protein Assay Kit (Thermo Scientific, 
Rockford, IL, USA) and stored at -20
o
C until utilization. The protein samples were mixed with 
NuPAGE LDS Sample Buffer (Life Technologies) and NuPAGE Reducing Agent (Life 
Technologies) and then boiled for 10 min at 70
o
C. Protein samples (15μg/well) were loaded 
on NuPAGE 4-12% Bis-Tris gels (Life Technologies) for electrophoresis under reducing 
conditions in MOPS buffer (Life technologies Ltd) followed by transferring the proteins onto a 
nitrocellulose membrane (Life Technologies). The membrane was washed in tris-buffered 
saline containing 0.3% Tween 20 (TBS-T; Sigma-Aldrich). After washing the membrane, it was 
blocked in 5% of non-fat milk solution in TBS-T for 1 hour. The membrane was then 
incubated, overnight, with the primary antibody. On the next day, the membrane was 
washed in TBS-T and then incubated with the appropriate horseradish peroxidase conjugated 
secondary antibody for 1 hour at room temperature. After washing, the signal was detected 
using Amersham ECL Plus™ Western Blotting Detection Reagent (GE Healthcare, Little 
Chalfont, UK). The film was scanned by Fujifilm Image Reader LAS-1000 Pro v.2.6 (Stockholm, 
Sweden) and the protein expression was quantified with the Fujifilm Multi Gauge v.3.0 
software (Stockholm, Sweden). The membrane was washed in TBS-T, stripped in Restore 
Western Blot Stripping Buffer (Thermo Fisher Scientific, Rockford, IL, USA) and incubated with 
a housekeeping gene for loading control. 
4.2.7 Immunohistochemistry 
Sections of paraffin-embedded cervical specimens (6 μm) were deparaffinized in xylene, 
ethanol 99-95% and hydrated in tap water. The antigen retrieval was done by boiling the 
sections in citric buffer for 30 min. To block for autofluorescence, sections were covered with 
CuSO4 for 2 hours. Sections were then blocked with 5% goat serum (GS) in phosphate buffer 
saline solution (PBS) for 1 hour. Sections were incubated overnight at 4
0
C with the primary 
antibody diluted in 1% GS, while negative controls were covered by 1% GS solution only. The 
next day, sections were incubated with the secondary antibody for 1 hour at room 
temperature. Sections were dehydrated (ethanol 95-99%) and then covered with Prolong
®
 
Gold Antifade Reagent with DAPI (Life technologies) and cover glasses .The average pixel 
intensity of antigen staining was measured in one representative area of cervical epithelium, 
submucosa, smooth muscle and submucosal blood vessel wall in specimen with Photoshop 
(version 12.0.4). 
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4.2.8 Cytokine analysis 
Cervical tissues homogenates were analyzed for the expression of cytokines, chemokines and 
growth factors by using magnetic beads multiplex immunoassays, Bio-Plex Assays (Bio-Rad 
Laboratories Inc., Irvine, CA, USA). Erythropoietin (EPO), granulocyte colony-stimulating 
factor (G-CSF), granulocyte-macrophage (GM)-CSF, Gro/KC (chemokine (C-X-C motif) ligand 1; 
CXCL1), interferon gamma (IFN-γ), interleukin (IL)-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-10, IL-
12p70, IL-13, IL-17A, IL-18, macrophage (M)-CSF, monocyte chemotactic protein 1 (MCP-1), 
macrophage inflammatory protein (MIP)-1α (CCL3), MIP-3α, regulated on activated, normal 
T-cell expressed and secreted (RANTES), tumour necrosis factor alpha (TNF-α) and vascular 
endothelial growth factor (VEGF) were analysed. The concentrations were determined using 
the Bio-Plex Assay Reader (Bio-Rad). The Bio-Plex Manager software optimizes the standards 
curves automatically and returned the data as Medium Fluorescence intensity (MFI) and 
concentrations in pg/ml.  
4.3 Ethics 
The clinical studies (paper I-III) were approved by the Institutional Review Board at the 
College of Medicine and Health Sciences, University of Rwanda and by the Ethics Committee 
at the University of Gothenburg. All women were contacted individually if laboratory analysis 
indicated a need for any treatment. In addition, participants were always informed about the 
HPV and cytology tests results and those with HSIL or cancer were referred for colposcopy. 
The preclinical studies (paper IV-V) were approved by the local ethics committee at the 
University of Gothenburg.   
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5 RESULTS AND DISCUSSION 
5.1 Paper I-III 
5.1.1 Differences in baseline characteristics between HIV+ and 
HIV- cohort 
In paper I, we studied the prevalence of LR- and HR-HPV strains and cytological abnormalities. 
We wanted to identify risk factors associated with the development of SILs and HR-HPV 
infection among 206 HIV+, 172 HIV- and 22 women with unknown HIV status in Rwanda. We 
also wanted to assess whether HPV screening could identify women with SILs. The HIV+ 
cohort and the HIV- cohort had similarities in baseline characteristics but also significant 
differences. The educational level was similar, the proportion of who never had smoked, the 
number of live births and abortions and the proportion who never had used IUD or hormonal 
contraceptives were similar in the HIV+ and the HIV- cohort. The HIV+ cohort was, however, 
older (46±8 years vs. 40±10 years, respectively), were more often widowed and had had 
more often a sexual debut before the age of 21 compared with the HIV- cohort. While 61% of 
Figure 7. Study participants’ flow chart 
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HIV- women reported to have had only one sexual partner, the corresponding figure for HIV+ 
women was 27%. Almost 90% of HIV+ women were under ART, 96% had a CD4+ count of 
more than 200 cells/mm
3
 and more than 80% had a HIV viral load at less than 400 copies/ml. 
Of women recruited in at outpatient gynecology clinics 2.9% were diagnosed with HIV, in line 
with previously reported prevalence figures in Rwanda [319]. The predominant part of all 
women at the HIV clinic at CHUK was under ART, had normal CD4 count and had low levels of 
viral load. The percentage of HIV+ patients under ART has increased significantly during the 
last years and in 2015 the percentage was 79% [320].  
In paper II, all women from the 400-patient cohort (cohort A; paper I) with HPV infections 
and/or with cytological abnormalities and an age-matched control group (137 women with 
HPV and/or with cervical cytological abnormalities and 100 controls; cohort B) were re-
screened for HPVs, cytological abnormalities and STIs/RTIs 9 months later. In paper III, cohort 
B was screened again at 18 months and 24 months for HPVs and cervical cytological 
abnormalities. Due to a higher prevalence of HPV in HIV+ women, there were more HIV+ 
women than HIV- women in cohort B (57.8% and 42.2%, respectively).  
5.1.2 HPV strains in HIV+ and HIV- women 
Baseline prevalence of being infected by any HPV was higher in HIV+ women than in HIV- 
women (27.7% and 11.6%, respectively; p<0.001; paper I). Baseline prevalence of PHR/HR-
HPV infections was 21.4% in the HIV+ group and 8.1% in the HIV- group (p<0.01). Among HIV+ 
women, it was more common to be infected by multiple HPV strains than among HIV- women 
(9.2% vs 1.7%, respectively; p<0.001). The most common HR-HPV strains detected were 
HPV16 (4.3%) and HPV52 (4.3%), which constituted 39.7% of all HPV-infections, while HPV18 
was only found in three of 400 participants. The low prevalence of HPV18 is in accordance 
with previous prevalence figures from Rwanda [321]. In addition, the prevalence of 32-34% in 
PHR/HR-HPV infections had been reported previously in Rwanda [321, 322], however, our 
cohorts consisted of an older population of women (89% were ≥35 years old) who were from 
different regions in Rwanda. This may have contributed to the differences in HPV prevalence.  
During the 24-month follow-up (paper II), all analysed HPV strains (prevalent at baseline and 
incident HPV strains combined) were detected among HIV+ and HIV- women but not HPV30, 
HPV43, HPV73 and HPV82. Of all 170 detected HPV infections, the most common strains 
detected were: HPV16 (13.53%), HPV52 (11.76%), HPV58 (5.88%) and HPV66 and HPV70 
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(4.71% each). Gardasil
®
 gives protection or cross-protection against HR-HPV strains HPV16, 
HPV18 and HPV31 [323], however, these strains constituted only 25.6% of all detected HR-
HPV infections and only 10.2% of all persistent HR-HPV infections. HIV+ women developed 
chronic HR- and LR-HPV infections (present at baseline and 24 months) in 56% and 33% of 
cases, respectively, while no HIV- women developed chronic HPV infections (p<0.001 for HR-
HPV). The cumulative incidence in HIV- and HIV+ women was 16% and 30%, respectively, for 
developing HR-HPV infections (p=0.0759). Among HPV negative women at baseline, HIV 
positivity enhanced the risk of contracting a HR-HPV infection (p<0.001).  
The high degree of HPV persistence in HIV+ women has been reported from studies in South 
Africa and Burkina Faso [324]. The high incidence of HPV infections in HIV+ women is in 
accordance with previous studies [324-326].  
5.1.3 Multiple HPV infections in HIV+ women 
In line with previous reports [327], HIV+ women were more commonly infected by multiple 
HPV strains than HIV- women specifically with multiple HR-HPV infection. Studies suggest 
that patients with multiple HR-HPV infections are more likely to have chronic LSIL [328]. 
Multiple HPV strains are also more common in HSIL than in LSIL [329]. Multiple HPV 
infections have been shown to be associated with larger cervical lesions [330].  
5.1.4 Cytological abnormalities common in HIV+ women 
At baseline (paper I), the percentage of women being infected by PHR/HR-HPV strains and 
presenting cytological abnormalities decreased with age both among HIV+ and HIV- women. 
Cytological abnormalities were observed in 24.3% of HIV+ women and in 9.9% of HIV- women 
(p<0.001). LSIL and HSIL/squamous cervical cancer (SCC) were diagnosed in 3.4% and 5.8%, 
respectively, of HIV+ women and in 4.7% and 1.2%, respectively, of HIV- women. HIV+ 
women with chronic HR-HPV infection presented with an abnormal cytology in 86% of cases 
during the 24-month follow-up (p<0.05; paper II). HIV+ women with persistent HR-HPV 
infections had a 38% risk of being diagnosed with HSIL or worse cytology at any time point 0-
24 months, however, at the last sampling occasion (normally at 24 months) only 8.7% (2/23) 
were diagnosed with HSIL. Among HIV- and HIV+ women negative for HPV at baseline, only 
3% were diagnosed with HSIL during the 24-months´ follow-up. 
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5.1.5 HPV screening to detect HSIL/cancer 
Rwanda is a country where healthcare resources are scarce and the number of physicians 
working in the country is low. Therefore, there is a need to find ways of screening out women 
at risk of HSIL and cervical cancer without overloading the healthcare system. Paper I shows 
that the sensitivity and specificity to detect HSIL or worse with HPV screening were 0.78 and 
0.87, respectively, which are relatively high values. Studies show that HPV screening 
compared with cytology increases the sensitivity to detect HSIL but with the cost of less 
specificity [331]. Combining HPV screening with cytology may improve cervical cancer 
screening [332]. HPV screening may tentatively be used particularly for risk patients such as 
patients with HIV, other immunodeficient patients and sex workers.  
5.1.6 Vaccine does not cover all prevalent HR-HPV strains 
The current vaccine used in Rwanda (Gardasil
®
) protects against HPV16, HPV18, HPV6 and 
HPV11. The vaccine may also give cross-protection against HPV33, HPV31, HPV45, and HPV51 
[333]. In view of HPV52 being prevalent in Rwanda, while HPV16 and HPV18 being much less 
common than in the Western world, our data indicate that the present vaccine may give an 
insufficient coverage against cervical cancer. An introduction of a vaccine with a broader HPV 
coverage, such as the nonavalent vaccine Gardasil
®
 9, into the vaccination program in the 
future may therefore be of particular importance in Rwanda. Pharmaceutical company-
sponsored phase III HPV vaccine trials in Africa are uncommon [334]. A variety of different 
HPV strains was detected among Rwandan women. HPV16 was the most common strain, 
however, it constituted only 13.45% of all HPV infections. Besides protecting against HPV6, 
11, 16 and HPV18, the currently used vaccine in Rwanda Gardasil
®
 may give cross-protection 
against HPV31 [323]. Based on the current data, Gardasil
®
 would, however, only have given 
protection against 1 out of 4 HR-HPV infections and 1 out of 10 persistent HR-HPV infections 
in our cohort. Therefore, Gardasil
®
 may be insufficient to give HPV protection in the Rwandan 
population. Our finding is consistent with other studies from East Africa, i.e., for example 
neither Cervarix
®
 (protects against HPV16 and HPV18) nor Gardasil
®
 are anticipated to give 
full protection against cervical cancer in Ethiopia due to different compositions of HPV strains 
such as a high prevalence of HPV52 [335]. Studies from The Democratic Republic of Congo, 
Zambia and Nigeria also show a higher prevalence of HPV52 than HPV16 [326, 336, 337].  
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5.1.7 Attitudes to cervical cancer screening 
Among HIV+ women, 27% had undergone a cervical cancer-screening test before the study 
compared with only 7% of HIV- women (p<0.001). While HIV+ women often were 
recommended to do a cervical cancer-screening test by their physician, HIV- women reported 
more frequently that the idea to do the test was their own. The reason for not undergoing 
cervical cancer screening was that many women reported not knowing about the 
test/cervical cancer. Financial reasons for not undergoing cervical cancer screening test was 
more common among HIV+ women compared with HIV- women (25% vs. 7%, respectively; 
p<0.001). In view of HIV being a risk factor for cervical cancer, it is notable that only 27.7% of 
HIV+ women had previously underwent a cervical cancer screening. Both in HIV+ and HIV- 
women, the unawareness of the test was high. About two third of the cohorts were not 
aware of the cervical cancer screening test, which is lower in comparison to countries such as 
Kenya and Uganda [338, 339]. A large proportion of HIV+ women reported economical 
reasons for not undergoing cervical cancer screening, which is commonly reported in 
developing countries [340]. Being widowed was more common among HIV+ women than 
HIV- women, which most likely contributes to a worse economical situation where health 
care issues may not be prioritized. Studies from Rwanda´s neighbour, the Democratic 
Republic of Congo, show that less than one third of women are willing to pay for a Pap smear 
test [341]. Information campaigns about cervical cancer, targeting HIV+ women are at 
present needed. Moreover, it is important to reduce the costs to undergo cervical cancer 
screening particularly for risk groups such as patients with HIV. 
5.1.8 Prevalence of RTIs in HIV+ and HIV- women 
In paper I (cohort A (N=400), the prevalence of different STIs and RTIs was reported. In paper 
III, cohort B (subgroup of cohort A; N=237) was called back for second testing of STIs and 
RTIs. STIs and RTIs were similarly distributed among women regardless of present co-
infection of HPV. No correlation between baseline characteristics and prevalence of 
STIs/RTIs at 9 months was observed. 
Candidiasis was the most prevalent genital infection and occurred in around 1 out of 4 
women younger than 35 years of age. The prevalence decreased with age both in HIV+ and 
HIV- women. Persistent candidiasis occurred more often in HIV- women (50% of cases) 
than in HIV+ women (7.7% of cases; p<0.05). One contributing factor was that HIV+ 
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women were on a regular basis in contact with the HIV clinic, which resulted in that more 
HIV+ women than HIV- women were treated for candidiasis and for other RTIs/STIs. Our 
prevalence figures of candidiasis are similar to the ones reported from Burkina Faso and 
Kenya [342-344]. T. vaginalis infection decreased with age in the HIV+ group, while it 
increased with age in the HIV- group. In cohort A, bacterial vaginosis occurred rarely among 
HIV+ women. However, in cohort B (i.e., subgroup of cohort A) the prevalence of bacterial 
vaginosis in HIV+ women was instead 8.8-22.6% and in HIV- women 15.0-18.0%. Even 
though all tests were performed with the same technique and at the same laboratory, 
technical issues with the analyses at baseline could be an explanation to the 
discrepancies in prevalence.  
5.1.9 Prevalence of STIs in HIV+ and HIV- women 
The 9-month incidence of syphilis was 10.9% in HIV+ women compared with 0% in HIV- 
women (p<0.01). Our data corroborates previous studies showing that syphilis is more 
common among HIV+ women than among HIV- women [345-348]. Our study revealed a 
higher prevalence of syphilis among HIV- women than previous studies [346]. The 
seroprevalence of syphilis of cohort A was 6% in HIV- women. Even if considering the small 
number of identified cases (6 of 100) among HIV- women, the seroprevalence of syphilis was 
noteworthy higher than the prevalence of 0.8% reported in the recently published study from 
Rwanda by Mutagoma et al. (2016) [346]. The percentage of women reported ever being 
infected by gonorrhea was higher in the HIV+ group compared with the HIV- group (p<0.001) 
and the percentage increased with age. Only a few women reported to have been infected by 
chlamydia, though, the proportion of who stated “I don´t know” was much higher in the HIV+ 
group than in the HIV- group (p<0.001). In cohort A, the number of women tested positive for 
HBsAg and anti-HCV was small both among HIV+ women (1.0% and 2.1%, respectively) and 
HIV- women (3.4% and 2.6% respectively).   
5.1.10 Rwandan women did not seek treatment for genital 
infections 
Among women who were tested positive for any STI/RTI at baseline, only 13/53 women 
(24.5%) contacted their health facility and got treatment. HIV+ women tended to seek 
treatment more often than HIV- women (36.4% and 16.1%, respectively; p=0.11). The 
number of patients treated for STIs/RTIs was low in both studied cohorts giving low 
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power to the statistical analysis. When considering all STIs/RTIs combined, 25% of HIV+ 
women were cured by treatment compared with 80% of HIV- women (n.s.). In HIV- 
women 4/5 STIs/RTIs (80%) and in HIV+ women 6/11 STIs/RTIs (55%) were cured by 
treatment (n.s.). In HIV- women 17/32 STIs/RTIs (53%) and in HIV+ women 15/25 
STIs/RTIs (60%) were resolved spontaneously (n.s.).  
Besides access to health care, some of the barriers preventing African women to seek 
treatment for genital infections have been extensively studied, i.e., the asymptomatic 
characteristics of many of genital infections, the way in which women perceive 
symptoms as not seriously enough to seek treatment, self-medication among women 
and the stigma attached to seek treatment for STIs [349]. As a consequence to this, 
complications may arise, e.g., leaving bacterial vaginosis untreated may lead to preterm 
labor and postpartum endometritis [350]. Well-known is also the risk to develop 
neurological complications if syphilis is left untreated [351]. 
5.1.11 Sexual behaviour among Rwandan women 
Seventy-five percent of HIV- women and 35% of HIV+ women reported to have had sex 
during the 9-month follow-up. The majority (87%) claimed to have had only one sexual 
partner and 41% never used condom for protection. More HIV- women than HIV+ 
women had had more than one sexual partner (20% vs 2.1% respectively; p<0.001) and 
never used condom (57.3% vs 14.6%, respectively; p<0.001) during the follow-up. We 
showed that most of HIV+ women claimed not to have had sex during the 9-month 
follow-up, while those who engaged in sexual activity claimed using condom, which is in 
line with previous studies in Africa [352]. However, our study shows that 30 out of 32 
cases of all infections observed at 9 months were new and were contracted during the 
follow-up period and that 82% were found among HIV+ women. The paradox of high rate 
of condom use among HIV+ and high rate of new infections has been demonstrated in 
several other African countries [353, 354]. Religious beliefs led to the less consistent use 
of condoms and that women had difficulties in negotiating condom use with their 
partners. The social desirability bias among HIV+ women may possibly also contribute to 
the paradox. Whether women are living with polygynous partners was not covered in our 
questionnaire. However, the paradox of high degree of STIs and few sexual partners 
among Rwandan women may possibly depend on STIs coming from polygamous partners.  
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While all unmarried HIV+ women and the majority of all married HIV+ women (82%) 
reported using condoms, the corresponding figures for unmarried and married HIV- 
women were 30% and 45%, respectively. Neither did the awareness of present STI affect 
attitudes to condom use among women. Almost all STI positive HIV- women (87.5%) 
reported not to have used condoms during sexual intercourse during the 9-month 
follow-up. The low percentage of condoms use in people who are HIV negative or not 
aware of HIV status is consistent with previous studies [355, 356]. Previous studies also 
show a low use of condoms among married and partnered people in SSA [357]. Condom 
use has decreased the last years in Rwanda and Uganda, while the use of injectable 
contraceptives has increased as a contraceptive method [358]. This may as a 
consequence, lead to an increased exposure to STIs including HIV.  
5.1.12  Participant’s characteristics associated with PHR/HR-
HPV infection and squamous intraepithelial lesions 
PHR/HR-HPV infection at baseline was associated with being divorced (OR=6.48; p<0.05) in 
HIV- women .It was also associated with ever having a genital gonorrhea infection (OR=4.88; 
p<0.001; AOR=3.01; p=0.07) and not knowing if having been infected by chlamydia (OR=1.78; 
p<0.01; AOR=2.61; p=0.12) in HIV+ women. HIV+ women have a higher degree of 
susceptibility to various genital infections and may be exposed to more genital infections 
than HIV- women [359]. PHR/HR-HPV infection at baseline was negatively associated with 
being under ART (OR=0.20; p<0.05) and a CD4 count>500 cells/mm
3
 (OR=0.26; p=0.09; 
AOR=0.18; p=0.05).  
Squamous intraepithelial lesions at baseline were associated with hepatitis B infection 
(OR=18.80; p<0.01; AOR=50.25; p<0.01), with Trichomonas vaginalis infection (OR= 6.71; 
p<0.05; AOR=30.98; p<0.05) and with PHR/HR-HPV (OR=16.89; p<0.001; AOR=16.33; 
p<0.001), in HIV- women. Both HPV and hepatitis B are transmitted sexually and previous 
reports suggest an association between hepatitis B and cervical HPV infections [360].  
In HIV+ women the number of live births (OR=1.44; p<0.01; AOR=1.55; p<0.05) was 
correlated with SIL, which is supported by previous reports [361]. HPV infection and the 
generation of HSIL may be facilitated by the immunosuppressive state pregnancy induces 
[362]. Being infected by PHR/HR-HPV (OR=14.65; p<0.001; AOR=13.02; p<0.001) was 
positively associated to SIL, while being under ARV (OR=0.14; p<0.01) and having a CD4 
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count>500 cells/mm
3
 (OR=0.07; p<0.05) were negatively associated to SIL. These findings are 
in line with previous reports showing that normal CD4 count in HIV+ patients leads to a 
decreased risk of being infected by HPV and being diagnosed with SIL [363, 364]. Still the 
prevalence of HPV was higher in the group of well-treated HIV+ women compared to HIV- 
women. ARV increases the chance of clearing HPV infections, however, some HR-HPV may 
still be difficult to eradicate under ARV [325]. Even if HIV+ patients under ARV may have 
normal CD4 count, HPV-specific T-cell immunity may be impaired contributing to the 
difficulty in clearing HPV infections [365].   
5.1.13  Risk factors for developing HR-HPV persistence and HSIL 
or worse cytology 
Being unmarried (OR=3.09; p<0.01), two or more life-time sexual partners (OR=2.59; p<0.05), 
being infected by HPV16/18 (OR=5.82; p<0.01; AOR=6.18; p<0.05), being infected by HR-HPVs 
other than HPV16/18 (OR=16.00; p<0.001; AOR=14.18; p<0.001) and HIV positivity (OR=9.46; 
p<0.001; AOR=6.72; p<0.01) at baseline were positively correlated, whereas age at first 
intercourse of 21 years or over was negatively correlated (OR=0.38; p<0.05) with HR-HPV 
persistence. Being infected by HR-HPVs other than HPV16/18 (OR=4.35; p<0.01; AOR=6.57; 
p<0.001) and other STIs/RTIs (OR=2.37; p<0.05; AOR=2.20; p=0.09) at baseline were 
positively correlated with LSIL. Being unmarried (OR=0.39; p<0.05; AOR=0.29; p<0.05) and 
using hormonal contraceptives (OR=0.49; p=0.09; AOR=0.35; p<0.05) were negatively 
correlated with LSIL. Being unmarried (OR=3.85; CI: 1.07-13.89; p<0.05), being infected by 
HPV16/18 (OR=4.99; p<0.001; AOR=3.74; p<0.05) and being infected by HR-HPVs other than 
HPV16/18 (OR=5.82; p<0.05; AOR=5.83; p<0.05) at baseline were positively correlated with 
development of HSIL or worse cytology. HIV positivity tended to be positively correlated to 
HSIL or worse cytology in the univariate analysis (OR=3.39; CI: 0.94-12.23; p=0.06).  
In a study from Brazil it was demonstrated that being unmarried was correlated with HPV 
re-infection among pregnant HIV+ women in Brazil [366]. Divorced, widowed or single 
women were demonstrated to be at higher risk of contracting incident HPV infections in a 
study from Costa Rica [367]. Unmarried women were at a greater risk of contracting HPV in a 
study from Canada [368]. In line with many reports, HR-HPV persistency was associated with 
development of cervical lesions. In HIV+ women with persistent HR-HPV infections, 86% 
presented with abnormal cytology at one or multiple occasions during the two-year follow-
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up. Previous studies have identified HIV status as an independent risk factor for HSIL [369, 
370]. While a higher proportion of HIV+ women than HIV- women developed persistent HR-
HPV infections and HSIL, HIV positivity was not retained in the multivariate analysis as an 
independent risk factor for the development of HSIL. Our study was, however, 
underpowered, to reveal such a correlation, since only few women developed HSIL in our 
cohort. It is suggested in some studies that older women more often than younger women 
develop persistent HR-HPV infections, [371-373]. Age was, however, not retained as a risk 
factor to HR-HPV persistence. Other large prospective cohort studies have also shown that 
age does not constitute a risk factor for HPV persistence [374-376]. 
Infection by HPV 16/18 at baseline was the only risk factor for HSIL but did not constitute a 
risk factor for LSIL. Infections at baseline, by other PHR/HR strains besides HVP 16/18 were, 
however, a risk factor for development of both LSIL and HSIL. While HPV persistence is a 
strong predictor of HSIL and risk of development of cervical cancer, LSIL may instead be 
associated with present chlamydia infection [377], trichomoniasis [378] and bacterial 
vaginosis [379]. Since the number of cases of individual STIs and RTIs was low, we did not 
stratify individual RTIs and STIs in the univariate analysis. While we could not observe a 
correlation between the use of oral contraceptives and HSIL//worse cytology, other studies 
show that the risk of cervical cancer increases with the duration of use of oral contraceptives 
[135]. Instead women ever using oral contraceptives were less likely to develop LSIL. A study 
from Colombia also demonstrated a reduced risk of LSIL among oral contraceptive users 
[380].  
5.1.14  SNP in IL28B correlated with susceptibility to HPVs 
infection 
Women contracting HPV had the C/T and T/T genotypes of the IL28B SNP (rs12979860) more 
commonly than women not contracting HPV in log-additive and in dominant models (p<0.05) 
.The polymorphism was, however, correlated neither with HR-HPV persistence and nor with 
the development of HSIL or worse cytology. No differences in the distribution of genotypes 
between HIV+ and HIV- women were observed. The IFNλ3 rs12979860 SNP has previously 
been linked to susceptibility for viral infections. Hence, the T allele was overrepresented 
among hepatitis C infected Uruguayan patients compared with uninfected controls [381] and 
was linked to susceptibility for hepatitis B infection in the Chinese population [382]. In 
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contrast, the T allele appeared slightly underrepresented in HIV-1 infected subjects [383]. In 
our study we found no correlation between rs12979860 SNP and HIV, but found that the CT 
and TT genotypes of the IFNλ3 rs12979860 SNP were more common among women infected 
by HPV than among women not infected by HPV. While the polymorphism is associated with 
clearance of hepatitis C [384, 385], the present data showed no association between the 
polymorphism and the chance of clearing HPV infection.  
5.1.15  Strengths and limitations of Paper I-III 
Our study has strengths and limitations: First, the cervical lesions were characterised based 
only on cytology test results, misclassification resulting in low sensitivity of cytology may have 
lead us to underestimate cervical abnormalities so that may be women were classified as < 
HSIL while they are really HSIL or worse but we know that up to now no other gold standard 
test available next to cytology. As many other follow up studies in long time, we also 
experienced a problem of participants lost to follow, which limited our power during the 
analysis, however we assume that the longitudinal design is the most suitable for the natural 
history of the disease study. As our study objectives were directed to sensitive issues, such as 
women sexual life, the results in relation to condom use and number of lifetime sexual 
partners should be interpreted with caution. In addition, as some of the research questions 
referred to past event, we could not exclude a recall bias during our results interpretation. 
However, in spite of limitations, to our knowledge, this is the first study report on natural 
history on cervical HPV cancer in Rwanda for a follow up time extended up 2 years of 
observations. In addition, our study population were suitable for natural history of cervical 
HPV cancer .In fact, most of the factors known to interact with the course of cervical cancer 
evolution such as smoking, HPV vaccination and cervical cancer screening were observed at 
low proportion. In addition, the study was designed to observe participants with multiple 
sampling point times. This gave us the opportunity to define persistence/clearance infection 
for at least two consecutives positive/negative test results. 
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5.2 Preclinical studies (Paper IV-V) 
5.2.1 Radiation did not induce morphological changes in rat 
cervix 
In paper IV, we wanted to assess how the immune system and antioxidative responses of the 
uterine cervix are affected by cervical irradiation. In paper V, we wanted to assess whether 
HBOT may reverse changes induced by cervical irradiation. Histological examination of the 
cervix showed that the irradiation seemed not to have induced any apparent changes of the 
cervix morphology. We did not observe any morphological changes (e.g. fibrosis, oedema) in 
the cervix 28 days after cervical irradiation, even though the equivalent dose of radiation 
given was large. Likewise, at earlier time points after cervical irradiation (1-14 days post-
irradiation) we did not observe changes in the morphology of the cervix [386]. In previous 
studies from the research group studying the pathophysiological processes following urinary 
bladder irradiation, the morphology of the urinary bladder 1-28 days post-irradiation seemed 
intact, although changes in oxidative stress and in the immune response occurred [291, 315]. 
Tissue changes induced by irradiation may take long time to develop. For example, irradiation 
of the rectum induces changes in the crypts 6 weeks after irradiation [295]. Typical 
radiological signs of lung fibrosis do not develop until 10 weeks after thoracic irradiation of 
the mouse [387]. Still, our findings indicate that tissue changes occur after cervical irradiation 
involving oxidative stress, antioxidative responses and immune-regulatory pathways. These 
responses may tentatively later result in advanced changes in the cervical tissue, such as 
fibrosis, similar to the clinical situation in patients exposed to radiotherapy due to for 
example cervical cancer.   
5.2.2 Radiation induces oxidative stress and changes in TLRs 
expression in rat cervix 
 Western blot showed the expression of TLRs 2-9 in control and irradiated cervical tissue. An 
increase in cervical TLR5 expression in response to cervical irradiation occurred in the cervical 
epithelium (p<0.05).  TLRs 2-9 were expressed in the epithelium. In the submucosa, TLR2, 
TLR4, TLR5, TLR6 and TLR9 were expressed. In the smooth muscle TLR2-9 except TLR8 were 
expressed. TLR4, TLR5, TLR6 and TLR7 were also expressed in blood vessels. MyD88 and TRIF 
were expressed in the cervical epithelium. Western blot analysis showed that toll-like 
receptor downstream molecules TRIF and NF-κB were increased in the irradiated cervix, while 
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MyD88 instead was decreased. SOD-1, SOD-2, catalase and 8-OHdG were expressed in the 
cervical epithelium and in blood vessels of the cervical submucosa. Cervical irradiation 
induced up-regulation of 8-OHdG, SOD-1 and catalase in the epithelium and in submucosal 
blood vessels of the cervix.  
Twenty-eight days after cervical irradiation, no obvious microscopic changes in the cervix 
could be observed. TLR5, TRIF and MyD88 expressions assessed by western blot were neither 
affected by cervical irradiation and nor by HBOT. However, TRIF expression in the cervix was 
lower in irradiated rats exposed to HBOT compared with those exposed to solely cervical 
irradiation (p<0.05). The expression of 8-OHdG was increased in the cervical epithelium after 
cervical irradiation, while HBOT reversed the expression to levels observed in control animals 
(p<0.05). Similarly, the expression of 8-OHdG in submucosal blood vessels tended to be 
increased by cervical irradiation and be reversed by HBOT, however, statistical significance 
was not attained (n.s.; n=5). Catalase was decreased in the cervix after irradiation and the 
decrease was normalized in the groups exposed to HBOT (p<0.01-0.05; n=5-11). The 
expressions of SOD-1 and SOD-2 were neither affected by irradiation nor by HBOT (n.s.; n=5-
11).   
The expression of TLRs (TLR1-9) in the female reproductive tract has been demonstrated in 
previous studies [184, 388-390]. It is also established that radiation induces TLR-driven 
mechanisms in cancer [391]. However, knowledge about how radiation affects the expression 
of TLRs in the normal cervical tissue is at present lacking. The most apparent finding of our 
study was that cervical irradiation induced increases of TLR5 in the epithelium concomitant 
with changes in cervical levels of TLR adaptor molecules MyD88, TRIF and NF-κB. The cervical 
epithelium expressed TLRs 2-9, which indicates that the cervical epithelium may respond to a 
high number of PAMPs and DAMPs. In the epithelium, TLR4, TLR6 and TLR9 were more 
expressed than TLR2, TLR3, TLR5, TLR7 and TLR8. Previous studies on cervical human 
epithelial cell lines showed the presence of all TLRs (1-9), where stimulation of TLR2, TLR3, 
TLR5 and TLR6 induced the release of cytokines [392]. The myometrium expresses TLR2, TLR3 
and TLR5 and stimulation of these TLRs may induce the release of pro-inflammatory and pro-
labour mediators [393-395]. TLRs (such as TLR2, TLR4 and TLR5) may use the 
MyD88/IRAK/NF-κB signal and the TRIF transduction pathways. Our data show that TRIF and 
NF-κB increased while MyD88 decreased in the irradiated cervix. The increase in TRIF 
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appeared in the epithelium concomitant with the up-regulation of TLR5. Studies show that 
TLR5 may interact with the TRIF pathway in the gut epithelium [396]. TLR5 may mitigate 
radiation-induced damage in the irradiated head and neck area of the mouse [397]. TLR5 
agonists may also reduce apoptosis after irradiation of the gut thereby improving tissue 
remodelling after rectal irradiation [398, 399]. The TLR5 agonist flagellin protects mice 
exposed to a lethal dose of whole-body γ-irradiation via MyD88 dependent pathways [400]. 
Radioprotective effects have also been shown to be generated via other TLRs such as TLR2, 
TLR3, TLR4 and TLR9 [401]. Western blot showed the presence of two bands of TLR8 (90 kDa 
and 95 kDa). Radiation tended to increase and decrease the expression of the denser and 
lighter band, respectively, which may indicate that TLR8 may undergo processing in response 
to irradiation. Previous studies show that TLR8 undergoes proteolytic processing in the 
endolysosomes to generate functional receptors in human monocytes and macrophages 
[402].  
Our study showed that oxidative stress (reflected by 8-OHdG staining) increased successively 
till 14 days after cervical irradiation, while SOD-1 and catalase increased in the cervical tissue 
already 24 hours after cervical irradiation. Changes in oxidative stress and antioxidants 
occurred particularly in the epithelium and in the submucosal blood vessels of the cervix. The 
present findings are in line with previous reports showing that oxidative stress and anti-
oxidative responses appear particularly in the urothelium and in submucosal blood vessels 28 
days following irradiation of the rat urinary bladder [403]. Our data may indicate that 
oxidative stress induced by cervical irradiation activated TLR5 and TLR-connected 
downstream molecules TRIF and NF-κB thereby mitigating oxidative stress via the release of 
antioxidants SOD-1 and catalase in the cervical tissue.  
Fourteen days following cervical irradiation the dominant effect on the cervical tissue was an 
anti-inflammatory response reflected by a reduction in important pro-inflammatory cytokines 
and chemokines. G-CSF, M-CSF, IL-10, IL- 17A, IL-18 and RANTES expressions in the cervix 
decreased two weeks after cervical irradiation (p<0.001-0.05). GM-CSF and MCP-1 tended to 
decrease but significance was not attained (p=0.05 and p=0.06, respectively). IL-17 was 
decreased concomitant with a decrease in G-CSF, M-CSF and IL-10 levels in the cervix. The 
present findings are in line with studies showing that pro-inflammatory mediators are 
reduced 14 days following urinary bladder irradiation [291, 403]. IL-17 plays an important 
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role in the female genital tract and may be released by Th17 cells and mucosal-associated 
invariant T (MAIT) cells [404, 405]. Our findings with a reduced IL-17 in response to cervical 
irradiation may indicate that radiation may lead to a weaker response to pathogens. An 
imbalance between Th1 and Th2 cytokines may also favour the development of adverse 
functional side effects to radiation and fibrosis. A number of studies have shown that Th17 
cells and IL-17 play important roles in the development of radiation-induced functional 
disorders and fibrosis, e.g., radiation-induced proctitis [290], liver fibrosis [406, 407] and 
radiation-induced pulmonary fibrosis [408, 409]. Interestingly, IL-10 and IL-17 levels in 
bronchoalveolar lavage, after pulmonary irradiation, were inversely correlated to the severity 
of pulmonary fibrosis [408]. Speculatively, our findings of reduced levels of IL-10 and IL-17 
may indicate that a pro-fibrotic microenvironment may have been developed in the cervix. 
The development of fibrosis seems, however, to take time since we could not either observe 
fibrosis in the rat cervical tissue 28 days after cervical irradiation (unpublished data).  
5.2.3 HBOT reverse the radiation induced-oxidative stress in 
rat cervix 
In an animal model we here show that HBOT may reverse changes in oxidative stress induced 
by ionisation radiation. Our previous study examining the pathophysiological processes 1-14 
days following cervical irradiation showed that irradiation may induce changes in the immune 
system of the cervix [386]. Several TLRs may be important for radioprotection [410]. 
Stimulation of TLR5 may reverse oxidative stress after irradiation of rat testis [411], may 
induce tissue remodelling and immune capacity in radiation-induced proctitis [398] and may 
stimulate hematopoietic progenitor cell proliferation in lethally irradiated mice [412]. In our 
previous study we observed an up-regulation of TLR5 and activation of the connected 
intracellular signalling pathways TRIF and MyD88 [386]. The present study shows that TLR5 
activation seems to have subsided 28 days after cervical irradiation. Albeit TLR5 activation 
was not observed, oxidative stress as assessed by 8-OHdG was present at 28 days after 
irradiation as well as a reduced expression of catalase in the cervix compared with controls. 
In our previous study we showed that SOD-1 and catalase were activated in the early events 
following cervical irradiation [386]. The expression of SOD-1 and catalase were normalized 14 
days following cervical irradiation. For catalase, the expression at 14 days even tended to be 
below normal expression, which is consistent with the current findings that catalase was 
decreased at 28 days after cervical irradiation. In rats exposed to cervical irradiation followed 
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by HBOT, the expression of catalase was normalized most plausibly as a consequence of 
reduced levels of oxidative stress.  
5.2.4 Strengths and limitations of Paper IV-V 
In paper IV and V, we are presenting results from western blot and immunohistochemistry 
technics. Both technics are characterised by a multiple steps of preparation and washing 
before the last step of protein expression visualisation and quantification. Even if we were 
using a well-validated protocol, we could not however minimize potential loss of protein 
during the whole process, which lead to underestimation of the reported results. This is why 
we reported the relative quantities. In addition, reporting results from 
immunohistochemistry should be associated with an excessive level of subjectivity. To 
minimize this limitation, sections were prepared and blinded before a second person read 
and analyse them. 
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6 CONCLUDING REMARKS 
6.1 Clinical studies (Paper I-III) 
To summarize, the results from paper I-III indicate the following: 
1. The overall prevalence of HPV infection and the prevalence in HR-HPV infection 
from this study are quite high even if they fit into the range of those previously 
reported in Rwanda. They also confirm that Rwanda is among East African countries 
with high prevalence in HPV infection; 
2. A high level in HPV incidence especially among previously negative tested women is 
bad indication that, if nothing is done, the predicted increase in HPV infections 
among SSA countries should become true; 
3. HPV 16, 52, 58, 66 and HPV70 were the most five prevalent types among Rwandan 
women, with HPV 16 being the most persistent and the most associated with 
cervical precancerous lesions. This supports previously provided evidences that the 
vaccine currently (Gardasil
®
) in use in Rwanda, should miss an important proportion 
of women and emphasise the need for a more protective vaccine; 
4. Consistent with other natural history of cervical HPV infection studies, most of the 
infections, even those related to HR-HPV types are transients. Only a small fraction 
of women were found with persistent infection. This small fraction corresponds to 
the fraction of women with HSIL who were presented to the study with HR-HPV 
infection. This constitutes a good tool for decision makers in Rwanda when 
designing a screening program; 
5. Unexpectedly, a fraction of 5/237 of women with HSIL was negative for HR-HPV and 
a non-negligible fraction of other cervical abnormalities were shown not related to 
HPV infection. If we agree with sensitivity of cytology test, this result requires 
confirmation from other natural studies at national level; 
6. A shown overall high prevalence in STIs/RTIs with endemic prevalence in 
bacterial vaginitis vaginal candidiasis and syphilis infection among HIV infected 
women, recall for an urgent need preventive measures in Rwandan population 
by targeting high-risk groups such as HIV infected women. This will reduce a 
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high proportion of women with cervical low-grade lesions and probably the 
incidence of HPV infection; 
7. HIV infection is the most risk factor for contracting HPV, HR-HPV infection. 
Furthermore, we showed that specific HR-HPV DNA test should be used as a 
cervical cancer screening test in HIV infected women; 
8. The results from this study show that women sexual behaviours such as early 
age at first intercourse, high number of lifetime sexual partners, being 
unmarried, history of gonorrhoea infection constituted risk factors for HR-HPV 
acquisition and persistence, especially among HIV infected women. The results 
also show that the infection by HR-HPV types other than HPV 16/18 and the 
infection by STIs/RTIs at baseline predicted more LSIL while the infection of any 
HR-HPV presented at baseline and being unmarried constituted the 
independent risk factors for developing HSIL; 
9. Finally, the C/T and T/T genotypes of the IL28B SNP rs12979860 increase women’s 
susceptibility to HPV infection. 
 
6.2  Preclinical studies (Paper IV-V) 
The results from paper IV and V lead us to the following conclusions: 
10. The uterine cervix expresses the TLRs 2-9; 
11. Radiation treatment induces upregulation of TLR5 coupled with 
depletion in important pro-inflammatory cytokines in rat cervix; 
12. Radiation treatment induces oxidative stress, in the rat cervix, which can 
be visualised by oxidant and/antioxidant markers; 
13. Radiation treatment induces long-lasting changes in oxidative stress in 
the uterine cervix and HBOT may tentatively be used to help women who 
have developed radiotherapy-induced adverse effects of the genital 
tract; 
14. More studies on effect of radiation in rat cervix are needed to validate its 
use as model in studies of immunological aspects of human cervix 
.  
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